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ABSTRACT
HANA LEE: MARGINAL STRUCTURAL COX MODELS WITH
CASE-COHORT SAMPLING
(Under the direction of Drs. Dr. Michael G Hudgens and Dr. Jianwen Cai)
A common objective of biomedical cohort studies is assessing the effect of a time-varying
treatment or exposure on a survival time. In the presence of time-varying confounders,
marginal structural models fit using inverse probability weighting can be employed to obtain
a consistent and asymptotically normal estimator of the causal effect of a time-varying treat-
ment. This document considers estimation of parameters in the semiparametric marginal
structural Cox model (MSCM) from a case-cohort study. Case-cohort sampling entails
assembling covariate histories only for cases and a random subcohort, which can be cost
effective, particularly in large cohort studies with low outcome rates. Following Cole et al.
[2012], we consider estimating the causal hazard ratio from a MSCM by maximizing a
weighted-pseudo-partial-likelihood. The estimator is shown to be consistent and asymp-
totically normal under certain regularity conditions. Computation of the estimator using
standard survival analysis software is discussed and results from a simulation study are
presented.
In the standard (associational) case-cohort Cox analysis, various methods have been pro-
posed to improve efficiency from maximum pseudolikelihood estimators of Prentice [1986a]
or Self and Prentice [1988]. As the presented theory of MSCM parameter estimator is
developed based on Self and Prentice [1988] we briefly review those methods and discuss
extension of the methods to the MSCM analysis. In addition, we proposed a new method to
improve efficiency of the case-cohort MSCM analysis from a biomedical study that aims to
evaluate the causal effect of treatment on a time to event. We seek to improve the efficiency
by multiple imputation method which can make fuller use of covariate information that are
available from full cohort. The proposed method is applied to the Multicenter AIDS Cohort
Study (MACS) and the Women’s Interagency HIV Study (WIHS).
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Chapter 1
Introduction
Biomedical cohort studies are often conducted with the goal of assessing the effect of a
time-varying treatment (or exposure) on a survival time. In such studies there may exist
time-dependent covariates which are simultaneously (i) confounders and (ii) affected by
prior treatment on the causal pathway from treatment to disease. In the presence of time-
varying confounders affected by prior treatment, standard methods such as Cox regression
modeling with time-varying covariates do not in general yield consistent estimators of the
causal effect of treatment [Robins, 1986, 1998; Robins and Rotnitzky, 1992; Herna´n, Brum-
back and Robins, 2001]. On the other hand, marginal structural models (MSMs) fit using
inverse probability weighting can be employed to obtain consistent estimators of the causal
effect of a time-varying treatment on an outcome of interest, even if there are time-varying
confounders affected by prior treatment [Robins, 1999].
For example, consider the Multicenter AIDS Cohort Study (MACS), an observational
study of HIV-positive homosexual men. Using data from MACS, Herna´n, Brumback and
Robins [2001] showed that (i) current CD4 count and Pneumocystis carinii pneumonia
(PCP) status were independent risk factors for death and were predictive of subsequent
treatment with zidovudine (AZT) and prophylaxis therapy (i.e., confounders), and (ii) pro-
phylaxis therapy was a protective risk factor for the development of PCP subsequently.
Thus, to assess the effect of AZT and prophylaxis therapy on mortality in MACS, a method
is required that can appropriately account for time-varying confounders affected by prior
treatment (in particular, PCP status). Applying standard (i.e., unweighted) Cox regres-
sion with time-dependent covariates to the MACS data, Herna´n, Brumback and Robins
[2001] reported an estimated hazard ratio of 1.85 (95% CI 1.49, 2.30) for AZT users versus
nonusers, suggesting that treatment increases the risk of death in HIV-positive homosex-
ual men, contrary to results from randomized clinical trials. On the other hand, fitting
a marginal structural Cox model (MSCM) with inverse probability weighting yielded an
estimated hazard ratio for AZT of 0.67 (95% CI 0.46, 0.98), in agreement with results from
randomized trials of AZT. The difference in hazard ratio estimates between the unweighted
Cox regression model and the MCSM with inverse probability weighting is not surprising
given the aforementioned established results about the (in)consistency of these estimators
in the presence of time-varying confounders affected by prior treatment.
Recently, Cole et al. [2012] considered fitting MSCMs via inverse probability weighting
in the presence of case-cohort sampling. The case-cohort study design is a cost-efficient
approach to estimate treatment effects in large cohorts with low event rates, when treatment
or covariate information is expensive. The design entails randomly selecting a subcohort
from the entire cohort. Covariate information is then collected only from the random
subcohort and from individuals that are observed to experience an event (i.e., cases), saving
cost and effort relative to obtaining covariate information from the full cohort. In addition to
being cost efficient, the case-cohort design enjoys other benefits. For instance, the subcohort
can serve as a basis for real time covariate monitoring during the course of the study.
Also, because the subcohort is chosen randomly, survival times to different diseases can be
analyzed using the same subcohort [Self and Prentice, 1988].
In the presence of case-cohort sampling, Cole et al. [2012] considered estimating the
causal hazard ratio of a MSCM via inverse probability weighting. Simulation studies indi-
cated the estimator proposed by Cole et al. [2012] can perform well empirically, however no
formal justification for their estimator has been developed to date. Therefore, following Cole
et al. [2012], we consider estimating the causal hazard ratio of a MSCM via inverse probabil-
ity weighting in case-cohort studies and establish consistency and asymptotic normality for
the estimator that maximizes a weighted-pseudo-partial-likelihood (WPPL) under certain
regularity conditions.
The approach utilized in this proposal entails standard counting process and martingale
theory. Using this formulation readily enables practical implementation of the methods
using existing survival analysis software. Framing the problem using counting processes
may also be helpful in future work, e.g., in fitting MSCMs to data from nested case-control
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studies or in the presence of competing risks. In the special situation that the subcohort
equals the full cohort, the proposed inverse probability weighted estimator is asymptotically
equivalent to the estimator in Robins [1999]. Moreover, in this case our proof gives an
alternative consistency and normality proof to Robins [1999], who did not utilize the usual
counting process framework.
The outline of the remainder of this document is as follows. Chapter 2 begins with an
introduction to methods for survival analysis primarily focusing on Cox models. A review
of case-cohort studies is next. Then we introduce MSCMs on the basis of causal inference
and potential outcome framework. This Chapter concludes with a review of some statistical
methods devised to improve efficiency in the standard Cox regression analysis with case-
cohort sampling. In Chapter 3 the estimator of the hazard ratio of a MSCM in the presence
of case-cohort sampling is introduced, and proofs of consistency of the parameter estimators
under the full and the case-cohort settings are shown. Also, we establish full distributional
theories of the parameter estimators under the full cohort and the case-cohort settings
in the same Chapter. How to implement a MSCM using existing software such as R or
SAS is described in Chapter 3.5, along with the simulation study results. Details to show
asymptotic distributional theory of the case-cohort MSCM parameter estimate are provided
in 3.6. In Chapter 4 we propose a new method that can improve efficiency in the case-
cohort MSCM analysis. We start from a review of general methods for MSCM case-cohort
estimators, including our proposed methods introduced in Chapter 3, and demonstrate
why the discussed methods devised to improve efficiency in the standard case-cohort Cox
regression analysis may not be applicable to the causal setting. We propose a new method
which aim to utilize all subject in the estimation and show numerical study results. The
proposed method is applied to a real observational HIV study data composed of two data
sets, the Multicenter AIDS Cohort Study and the Women’s Interagency HIV Study.
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Chapter 2
Literature Review
2.1 Cox Models
Here, we assume a study consists of n unique individuals who are indexed by i = 1, ..., n.
Let Ti denote failure (or survival) time of a subject i in a study, where T = 0 represents
the time of initiation of follow-up and τ represents study end point. We essentially as-
sume that the failure time is on continuous basis. Let Ci denote the time of censoring
and Xi = min(Ti,Ci) denote the observed time from the subject i. δ(Xi) = I{Ti < Ci} is
an event indicator where I{⋅} is an usual indicator function. In addition, let p × 1 vector
of Zi(Xi) = (Z1i(Xi), ...,Zpi(Xi)) denote time-dependent covariates information collected
from the subject i. Throughout we assume (Xi, δi,Zi)(i = 1, ..., n) be n independent repli-
cates of (T, δ,Z) that Z is bounded. Also, let Ni(t) be a stochastic process which denote the
number of failures of subject i by time t. We use the notation dNi(t) to indicate the number
of events of the subject i occurred in [t, t+ dt) for sufficiently small dt. Since failures occur
in continuous time, we only allow jumps of size 1 and no simultaneous jumps can occur in
[t, t + dt) for the process Ni(t). Let Yi(t) = I{Ti ≥ t,Ci ≥ t} denote whether an individual
is still alive and being able to be observed (to fail) at time t, having a left-continuous sam-
ple paths. This process is called “at risk” process. Then the data for the ith participant
(Xi, δi,Zi) can be rewritten as {Ni(u), Yi(u),Zi(u) ∶ 0 ≤ u ≤ t}.
In biomedical studies, we are often interested in identifying/quantifying risk (or prognos-
tic) factors related to response. Cox regression models, including Cox proportional hazards
models, introduced by Cox [1972] are the most commonly used approach to explore (or
adjust) for the effect of covariates that may be associated with that outcome. Let λ(t∣Z(t))
denote the hazard (or risk) of being failed associated with Z(t), i.e.,
λ(t∣Z(t)) = lim
dt→0
Pr(t ≤ T ≤ t + dt∣T ≥ t,Z(t))/dt.
Then Cox models are given by
λ(t∣Z(t)) = λ0(t) exp{β′0Z(t)} (2.1)
where λ0(t∣Z(t)) is an unknown baseline hazard and β0 = (β0,1, ..., β0,p) is a set of unknown
regression parameters. λ0(⋅) describing how the hazard changes over time at baseline levels
of covariates, i.e., Z(t) = 0 for all t ≥ 0. β0 describes the effect of covariates on the hazard
changes over time. Under this model, we can compare two hazards under different covariate
levels (e.g., treated or untreated) in the logarithm scale. For instance, consider two obser-
vations i and i∗ that differ in their covariate values at time t by Z(t) and Z∗ respectively.
Then the hazard ratio for two observations is
exp{β′0Z(t))}/ exp{β′0Z∗(t)} = exp{β′0(Z(t) −Z∗(t))},
and therefore the log of the hazard ratio β′
0
(Z(t)−Z∗(t)) can be explained by the parameter
β0. When Z(t) ≡ Z for all t ≥ 0 then this models are also referred to as the proportional
hazards models since the hazard ratio at any time t is independent of time t. Explicitly, the
hazard ratio for two observations i and i∗ in the above example is
exp{β′0Z}/ exp{β′0Z∗} = exp{β′0(Z −Z∗)}
which is constant over time t.
λ0(⋅) is an unknown function and parametric distributional assumptions such as uni-
form, exponential, weibull on λ0(⋅) is available. Other than distributional assumption, a
monotonic or step function assumption can also be made. However, Cox [1975] proposes a
partial likelihood approach which enables to estimate the parameter of interest β0 in (2.1)
while the λ0(⋅) remains unspecified. Consistent estimator for β0 can be obtained by using
the partial likelihood score function
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U(β) =
n
∑
i=1
δi{Zi(Xi) − S
(1)(β0,Xi)
S(0)(β,Xi)
} (2.2)
where S(k)(β,Xi) = n−1∑ni=1 Yi(Xi)Z⊗ki (Xi) exp{β′Z(Xi)} for k = 0,1,2 under standard
independent censoring assumption. Here, we define a⊗0 ≡ 1,a⊗1 ≡ a, and a⊗2 = a′a which is
defined by the p×p matrix with (i, j)th element aiaj for p×1 vectors a. The maximum par-
tial likelihood estimator βˆ, defined as the solution to the score equation U(βˆ) = 0, is shown
to converge in distribution to Normal with mean zero and a covariance matrix which can
consistently be estimated by −{∂U(β)/∂β∣
β=βˆ
}−1 based on martingale formulation (Ander-
sen and Gill [1982]). Using an integral representation, log-likelihood function corresponding
to (2.2) can be written by
l(β) =
n
∑
i=1
∫
τ
0
β′Zi(u) − log[
n
∑
l=1
Yl(u) exp{β′Zl(u)}]dNi(u). (2.3)
The theory and application of the Cox models almost always assumes an exponential
form for the relative risk function on regression variables, however, other regression forms
such as a linear relative risk function (e.g., 1 + β′
0
Z) are more natural to use in some
applications. Prentice and Self [1983] addresses that a linear relative risk regression model
may provide a more convenient framework for studying epidemiologic risk factor interactions
than an exponential relative risk regression. Using the same counting process formulation of
Andersen and Gill [1982] but with some more stability and regularity assumptions, Prentice
and Self [1983] establishes asymptotic distribution theory for a class of intensity function
regression models in which the usual exponential regression form is relaxed. In Prentice
and Self [1983], (2.1) is extended by
λ(t∣Z(t)) = λ0(t)r{β′0Z(t)} (2.4)
and (2.3) is modified by
l(β) =
n
∑
i=1
∫
τ
0
β′Zi(u) − log[
n
∑
l=1
Yl(u)r{β′Zl(u)}]dNi(u), (2.5)
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where r{⋅} is a generalized relative risk function, which is an arbitrary non-negative twice
differentiable function assumed to be locally bounded away from zero in some neighbor-
hood of β0. Estimators obtained by solving ∂l(β)/∂β = 0 is shown to be consistent and
asymptotically normal, based on asymptotic normality of the score function along with con-
sistency of the observed information matrix −n∂2l(β)/∂β2. Some stability and regularity
conditions, beyond those of Andersen and Gill [1982], are required to show the consistency
of the observed information matrix.
2.2 Causal Inference and Marginal Structural Cox Models
The purpose of this chapter is to review causal inference on the basis of potential outcome
framework, relevant notation and assumptions, and finally to review the MSCMs. Before
we start reviewing what the causal inference is, we address that under what circumstances
standard statistical methods may fail to provide causal inference.
The term time-varying confounder is commonly used for time-varying risk factors of
an outcome of interest that also predicts the subsequent exposure (or treatment). Post-
treatment variables potentially affected by treatment and also affecting the response are
referred to as intermediate variables. Unlike randomized clinical trials, many observational
studies with long-term follow-up period often incorporate time-dependent covariates which
are simultaneously confounders and intermediate variables on the causal pathway from
exposure to disease. As a result, it may not be possible to obtain causal interpretation
from the parameter estimator obtained using standard statistical methods. It is also true
when the time-to-event response is considered. Standard methods of using the ordinary
Cox models (2.1) or (2.4) adjusting for the time-dependent covariates may fail to provide
appropriate causal effect of the exposure on an outcome of interest.
In the presence of such time-varying confounders, marginal structural models (MSMs,
Robins [1999]), or marginal structural Cox models when the failure time is of interest,
are powerful tools for assessing causal effects of time-varying treatments on an outcome of
interest. MSMs are used increasingly to provide semi-parametric estimates of total (Bodnar
et al. [2004]), joint (Robins, Herna´n and Brumback [2000]; Herna´n, Brumback and Robins
[2000]), and direct/indirect (VanderWeele [2009b]) causal effects of exposures on an outcome
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in epidemiologic studies.
In following sections, we give introduction to causal inference with relevant concepts,
notation, and assumptions to understand MSMs as tools to draw causal inference. Hereafter
we assume an observational study wherein confounding effect exists, which interested in
evaluating treatment effect on a participant’s failure time such as HIV studies for example.
2.2.1 Causal Inference and Potential Outcomes
Most causal inferences are based on the idea of potential outcomes under all possible
treatment assignments, introduced by Neyman [1923]. The potential outcomes, which in-
clude observed and unobserved outcomes, are sometimes called counterfactual outcomes
(or simply counterfactuals) since these outcomes could have happened contrary to what we
actually observed. In this framework, causal inference can be considered as a missing data
problem letting the potential outcomes as missing data, especially the unobserved outcomes
to be the missing outcomes.
Below we modify some of the notation introduced from earlier section to be more suitable
to a hypothetical biomedical study and to the causal inference framework. Capital letters
represents random variables and lower case letters represents values of the random variables
or constants, the same as before. Now, let Ai(t) be the treatment vector of subject i where
t denotes the time since the beginning of the subject’s follow-up. Let Li(t) denote a vector
of assembled covariates such as CD4 counts and PCP level from subject i at time t. The
subscript i will sometimes be suppressed in our notation since we assume Ai(t) and Li(t)
are random vectors for each subject drawn independently from a distribution common to
all subjects. Let V represent baseline covariates which can be a part of L(0). A(t) and
L(t) are defined to be zero when t < 0. Note that a p × 1 covariate vector Z(t) introduced
from earlier section equals to {A(t),L(t)}.
Potential (Counterfactual) Outcomes In the context of causal inference, overbars
are used to represent history up to and including time t such that A(t) = {A(u); 0 ≤ u ≤ t}
and L(t) is defined analogously, assuming that decisions related to treatment at t is made
after obtaining the covariate information at t, i.e., L(t) is temporally earlier than A(t). Let
⊥ denote statistical independence; for example, A ⊥ B∣C denotes A is independent of B
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given C.
a represents each possible treatment plan; a = {a(t) ∶ 0 ≤ t ≤ τ} where τ is the study
end point, same as before. Each possible value of a can be interpreted as a pre-specified
treatment plan. Practical examples of a might be never treated (i.e., a(t) = 0 for all
t ∈ [0, τ]), treated starting at a pre-specified time t1 (i.e., a(t) = I[t > t1]), treated from
baseline (i.e., a(t) = 1 for all t ∈ [0, τ]), etc. Then Ta represents a random variable implying
a subject’s potential failure time had (possibly contrary to what we observe from actual
study) the subject been treated with history a. For example, one can use notation T
0
(t) to
represent a subject’s potential failure time if he had treated from baseline, Tt1(t) if he had
treated since time t1 > 0, and T∞ if he had never treated. At each time-to-event t such as
death or disease occurrence time, a set of three different failure times (T
0
(t), Tt1(t), T∞(t))
comprises potential outcomes.
Assumptions Most causal models that are based on the idea of potential outcomes rely
on the following four assumptions.
1. Consistency In reality, we only observe the outcome T with a subject’s actual
treatment history A, i.e., T = T
a=A
= T
A
. This identity is called the fundamental
“consistency” assumption that links the potential failure times Ta to the observed
data (T
A
,A).
2. No unmeasured confounders There are no unmeasured confounders for the effect of
A(t) on T if, for all a,
Ta ⊥ A(t)∣A(t−),L(t) (2.6)
holds (Robins [1999] and Herna´n, Brumback and Robins [2000]).
3. Positivity We say that positivity assumption holds if Pr[A(t) = a∣L(t) = l] > 0 for
all a ∈ {0,1} and l such that Pr[L(t) = l] ≠ 0.
4. No misspecification of the model As we always assume that the model we employ
is a correct model to analyze data, a causal model to estimate the effect of treatment
is assumed to be correctly specified.
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Informally, consistency means that the outcome for every treated individual equals to the
subject’s outcome if he/she had received treatment, and the outcome for every untreated
individual equals to his/her outcome had the subject remained untreated. No unmeasured
confounders means that the risk of failure under the potential treatment history a among
the treatment group equals to the risk under the same potential treatment history among
untreated group for each a. Therefore the treated and untreated groups are exchangeable
as in a randomized trial. For this reason, the assumption is also called “exchangeability”
or “sequential randomized assumption” in some articles since it implies that potential out-
comes are exchangeable regardless of treatment history given all relevant confounder history
as if in a randomized trial. However, if there exists any unmeasured confounder that pre-
dicts A(t) at time t then the potential outcomes are no longer independent of treatment
history. Positivity simply means that the conditional probability of receiving every value of
treatment is greater than zero. No missspecification of the model assumption is the natural
assumption to make any statistical inference and may be tested using sensitivity analysis.
In general, the no unmeasured confounders assumption is a crucial assumption to draw
causal inference using some causal models but is not statistically testable. A more complete
studies on these condition and causal inference can be traced back to Rubin [1974], Rubin
[1976], Rubin [1980], Robins [1986], Greenland and Robins [1986], and Robins [1987].
Causal and Statistical Exogeneity Informally, a treatment process is referred to be
a “causally exogenous” process if the conditional probability of receiving a treatment A(t)
given past treatment and (measured and unmeasured) prognostic factor history depends
only on past history of treatment history A(t−). Mathematical definition of causal exogene-
ity may vary across different articles. Definitions of presented in this proposal are adopted
from Herna´n, Brumback and Robins [2001]. The article defines a treatment process to be
“causally exogenous” if
Ta ⊥ A(t)∣A(t−) (2.7)
for all treatment plans a, which is equivalent to state that Ta is independent of A(t). Also,
definition of “statistically exogenous” of treatment process is adopted from the same article
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which is given by
L(t) ⊥ A(t)∣A(t−). (2.8)
This implies that conditioning on treatment history before time t, probability of receiving
treatment at time t does not depend on the history of measured time-dependent prognostic
factors up to t. It can be seen that (2.8) is a necessary condition for A(t) to be causally
exogenous, but (2.8) does not imply (2.7) due to the possibility of unmeasured confounders.
Following Robins et al. [1992], Herna´n, Brumback and Robins [2001] also defined that there
are no unmeasured confounders for the effect of A(t) on T if, for all a,
Ta ⊥ A(t)∣A(t−),L(t) (2.9)
holds.
Robins [1999] showed that statistical exogeneity implies causal exogeneity under the
assumption of (2.9). Also it is well recognized that treatment parameters of a correctly
specified association model have causal interpretation if the treatment process is causally
exogenous. Therefore, causal inference can be drawn from using standard association models
if condition (2.8) is true assuming that (2.9) holds.
2.2.2 Marginal Structural Cox Models
Robins [1999] introduced MSMs combined with inverse-probability-treatment-weights
(IPTW) as a method to draw causal inference in the presence of confounding, which rely
on the potential outcome framework. IPTW can be considered a type of inverse sampling
weights to account for missing data or sampling bias problem. By weighting observations via
IPTW, we can reflect back the balanced design from observational data having confounding
effect (under the assumptions described from Chapter 2.2.1).
We first review IPTW and then describe MSCMs after.
Inverse-Probability-Treatment-Weighting Suppose that we can correctly model the
probability of receiving treatment at time t given past treatment history and covariate his-
tory, i.e., Pr[A(t)∣A(t−),L(t)]. Then we could measure the degree of statistical exogeneity
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of the treatment process through time t by calculating a following weight at t:
W T (t) =∏
k≤t
Pr[A(k)∣A(k−)]
Pr[A(k)∣A(k−),L(k)] , (2.10)
which is referred to as inverse-probability-of-treatment-weights (IPTW). Under the four
assumptions of consistency, no unmeasured confounders, positivity, and no misspecification
of the model to estimate the weights, we can create a hypothetical population by weighting
each subject at risk at each failure time with (2.10). This hypothetical or weighted study
population is known as the pseudo-population. Robins [1999] and Lemma A.1 of Herna´n,
Brumback and Robins [2001] proved that L(t) no longer predicts A(t) in each pseudo-
population created at each failure time t (note that (2.10) equals to 1 at any time t if L(t)
does not predict A(t)∣A(k−), i.e., the treatment process is statistically exogenous). Then it
follows that the treatment process is causally exogenous in the pseudo-population under the
assumption of no unmeasured confounders. Thereby one can employ standard association
models to estimate the treatment effect which can further be interpreted as a causal effect.
As the same manner, we can effectively adjust bias occurred by censoring due to loss to
follow-up when time-to-event data is considered. This can be done by considering inverse-
probability-of-censoring-weights (IPCW), say WC , where
WC(t) =∏
k≤t
Pr[C(k) = 0∣C(k−) = 0,A(k−)]
Pr[C(k) = 0∣C(k−) = 0,A(k−),L(k)] , (2.11)
under the assumptions of independent censoring and no unmeasured confounders for cen-
soring. Here, C(k) = 0 means a subject remains uncensored prior to time k and C(k) = 1
means censored at that time.
Robins [1997] first introduced IPTW, which is called unstablized weights, as a tool to
adjust non-ancillary treatment process in the observational study, however, it has a slightly
different form than (2.10). Stablized weights has the same denominator as in (2.10) but the
numerator in (2.10) is always 1 regardless of time t. Therefore it is a nondecreasing function
of t since the product of probabilities in the denominator decreases over time. Robins,
Herna´n and Brumback [2000] suggests stabilized weights which is the IPTW shown in (2.10)
as a substitute of the unstablized weights, and this is by far the most widely used IPTW.
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Besides this, truncated (Cole and Herna´n [2008]) and normalized (Xiao, Abrahamowicz and
Moodie [2010]) weights are also introduced and these weights can be considered as types of
stablized weighs as they all aim to adjust variability of IPTW and make it stable over time.
Stablized weights are generally recommended to employ in practice as they lead to, often
remarkably, more efficient estimators of causal treatment effect.
When survival data is considered, inverse-probability-weights (IPW) defined by W (t) ≡
W T (t) ×WC(t) are the stabilized weights. For estimation of random weights W (t) see
Herna´n, Brumback and Robins [2000], Herna´n, Brumback and Robins [2001], and Cole and
Herna´n [2008]. Since investigators should assume that the model to estimate IPW (e.g., a
logistic model), sensitivity analysis results with different model specifications will help to
see validity of the correct model assumption in practice.
Marginal Structural Cox Models Marginal Structural Cox Models (MSCMs) are
given by
λTa(t) = λ0(t) exp{β′0f(a(t))} (2.12)
where λTa(t) is the hazard of failure at time t if all subjects in a study population had
followed treatment history a through time t, λ0(⋅) is an unspecified baseline hazard func-
tion corresponding to the hazard if all subject had been untreated, and β0 is an unknown
parameter vector. If we are interested in current treatment effect of zidovudine on AIDS
so that f(a(t)) in (4.1) becomes a(t), and exp(β0) has a causal interpretation such as the
ratio of the hazard of getting AIDS at any time t if all subjects had been continuously
exposed to zidovudine compared with the hazard rate at t had all subjects remained un-
exposed. This model is a causal model for the marginal distribution of the variables Ta
which is the potential outcomes that are generally unobserved. Hence estimation of the
causal log rate ratio β0 cannot be made directly through this model. In the absence of
confounding, association implies causation thereby we can use the standard Cox regression
model to obtain causal estimates. As mentioned the above, Robins [1999] showed that we
can create a psuedo-population via IPW at each failure time t in which time-dependent
prognostic factors no longer predict treatment history. Robins [1999] also proved that the
causal relationship between treatment and hazard in the psuedo-population is the same as
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in the original study population, and the estimator of treatment effect obtained by using
the standard Cox regression model based on the psuedo-population converges in probability
to β0 in (4.1). Therefore the estimator of treatment effect obtained by using the ordinary
time-dependent Cox model adjusting (only) for the treatment, after weighting each individ-
ual at each failure time by IPW, can have causal interpretation as it converges in probability
to β in (4.1).
2.3 Cox Models with Case-cohort Sampling
The case-cohort study proposed by Prentice [1986a] and Self and Prentice [1988] is a
cost-effective design particularly when large epidemiologic cohort studies with rare disease or
infrequent event such as HIV studies are considered. This design involves random selection
of a subcohort (or a stratified random sample) from the entire cohort and all participants
who experience the event of interest, henceforth cases. By monitoring covariate information
only for a random subcohort and for all cases we can gain cost and effort saving. The
subcohort constitutes the comparison set of cases occurring at a range of failure times as
well as a basis for covariate monitoring during the course of cohort follow-up (Self and
Prentice [1988]).
Prentice [1986a] considers Cox modeling on time-to-response case-cohort data. Suppose
that a random subcohort C˜ of size n˜ is selected from the entire cohort C of size n. Then the
log partial likelihood is modified by
l∗(β) =
n
∑
i=1
∫
τ
0
β′Zi(u) − log[ ∑
l∈C˜∪{i}
Yl(u)r{β′Zl(u)}]dNi(u). (2.13)
in the presence of case-cohort sampling, which is termed a log pseudolikelihood by Prentice
[1986a].
Self and Prentice [1988] provides a full range of asymptotic theory for parameter estima-
tors of the Cox models in the presence of the case-cohort sampling using a slightly different
log partial likelihood form
l˜(β) =
n
∑
i=1
∫
τ
0
β′Zi(u) − log[∑
l∈C˜
Yl(u)r{β′Zl(u)}]dNi(u). (2.14)
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Estimators obtained by solving ∂l˜(β)/∂β = 0 are shown to converge in probability to β0
and asymptotically normally distributed via same techniques as in Andersen and Gill [1982]
and Prentice and Self [1983], i.e., by showing asymptotic normality of the score function
along with consistency of the observed information matrix. It is also shown that estimators
obtained by solving ∂l∗(β)/∂β = 0 and ∂l˜(β)/∂β = 0 converge in probability to the same
quantity, β0, in Self and Prentice [1988].
Several other authors such as Binder [1992] and Lin and Ying [1993] expand the idea
of the case-cohort design and provide estimating equations to obtain estimators in more
general settings. Binder [1992] describes how to create a family of survey-related sampling
plans, and provided a procedure for fitting the proportional hazards models to survey data
with complex sampling designs including the case-control sampling. Estimating equation
proposed in the article is an extension of the standard score function equation in (2.2), with
incorporating probability of being sampled. In particular, Binder [1992] proposes a score
function given by
U∗(β) =
n
∑
i=1
wiδi{Zi(Xi) − S
∗(1)(β0,Xi)
S∗(0)(β,Xi)
},
where now the statistics were modified by
S∗(r)(β,Xi) = n−1
n
∑
i=1
wiYi(Xi)Z⊗ki (Xi) exp{β′Z(Xi)}
for k = 0,1,2, and wi is the inclusion probability for the subject i, i.e., wi = 1/πi if the sub-
ject i is selected in the sample and 0 otherwise. Estimators obtained by solving U(β) = 0
are then shown to be asymptotically normally distributed. Lin and Ying [1993] provides a
general solution to the problem of missing covariate data under the Cox models, considering
case-cohort data as a possible example of missing covariate data. The estimating function
proposed in the article is an approximation to the partial likelihood score function with
full covariate measurements, which reduces to the score function of Self and Prentice [1988]
in the special setting of the case-cohort designs. The approximate partial likelihood score
function is given by
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U˜(β) =
n
∑
i=1
δiHi(Xi){Zi(Xi) − S˜
(1)(β0,Xi)
S˜(0)(β,Xi)
}
where Hi is a p × p diagonal matrix with indicator functions {H1i(⋅), ...,Hpi(⋅)} as the
diagonal element with H1i(Xi) being an indicator whether Zji(Xi) is available at failure
time Xi, S˜
(k)(β,Xi) are defined by n−1∑ni=1H0i(Xi)Yi(Xi)Z⊗ki (Xi) exp{β′Z(Xi)} for k =
0,1,2 with H1i(Xi) being an indicator I{Hji(Xi) = 1} for all j = 1, ..., p. Then approximate
partial likelihood estimators (APLE) are the root to the estimating equation U˜(β) = 0. The
resulting parameter estimators are consistent and asymptotically normal with a covariance
matrix for which a simple and consistent estimator is provided. Also, the asymptotic theory
of the APLE are established on regularity conditions that are much simpler to interpret and
check than those in Self and Prentice [1988].
Despite the efficiency of the sampling methods, applications of the case-cohort designs
had been limited because of perceived analytic complexity, especially on the variance com-
putation proposed from Self and Prentice [1988]. Self and Prentice [1988] variance estimator
is not easy to implement as it includes computation of covariances between score contri-
butions from pairs of different risk sets. Simple robust variance estimators are proposed
by Lin and Ying [1993] and Barlow [1994] as a solution to the computational challenges
in variance computation, and also practical implementation of the Cox models to the real
case-cohort data is addressed by Therneau and Li [1999] and Barlow et al. [1999]. Therneau
and Li [1999] describes how to obtain Self and Prentice [1988], Barlow [1994], and Lin and
Ying [1993] parameter estimators along with their variance estimators using standard soft-
ware packages, with SAS and S-Plus as particular examples. Barlow et al. [1999] illustrates
weighting methods as model fitting techniques and provides a SAS macro that computes
the weighted estimates and the robust covariance matrix.
2.4 Statistical Methods to Improve Efficiency
In the standard associational case-cohort Cox analysis, various methods have been pro-
posed to improve efficiency from maximum pseudolikelihood estimators of Prentice [1986a]
or Self and Prentice [1988]. In this chapter, we briefly review some of these methods who
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seek to improve efficiency of the hazard ratio estimation compared to Prentice [1986a] and
Self and Prentice [1988].
Unweighted Psuedo-Partial Likelihood Estimators As described in 2.3, Prentice
[1986a] proposed a pseudo-likelihood approach for the hazard ratio parameter estimation in
the Cox model along with heuristic procedures for parameter estimation when the case-
cohort design is applied. Asymptotic distribution theory of the case-cohort maximum
pseudo-likelihood estimator was developed by Self and Prentice [1988] using martingale
technique and finite population convergence results. Both Prentice [1986a] and Self and
Prentice [1988] do not accommodate case sampling or stratified sampling of controls, i.e.,
they considered unweighted pseudo-likelihoods.
Unweighted Psuedo-Partial Likelihood Estimators After Prentice [1986a] and
Self and Prentice [1988], various methods have been proposed as means of improving the
efficiency of the hazard ratio estimation (compared to Prentice [1986a] and Self and Pren-
tice [1988]) in the standard (associational) case-cohort Cox regression analysis. Chen and
Lo [1999] studied a different class of estimating equations than Prentice [1986a] and Self
and Prentice [1988] by constructing different risk sets in the estimating equations. They
proposed to utilize complete information of all cases when calculating ratio of weighted av-
erages based on risk set information inside the estimating equations. In particular, authors
proposed three different estimating equations which all use the empirical distribution of
covariate Z among cases to the conditional joint distributions of (Z,X) among cases, but
use different estimators of p = pr{δ(Xi) = 1}. Chen et al. [2001] found an optimal sample
reuse method via local averaging, and proposed a unified weighted estimating equation,
that can be used in various sampling design, to improve efficiency.
Time-Varying Inverse-Sampling-Weights Barlow [1994] and Barlow et al. [1999] con-
sidered estimators based on weighted pseudo-likelihood estimation. At each failure time,
contribution of cases and nonfailures (controls) at risk are weighted by either fixed or time-
varying inverse-sampling-weights (ISW) to account for subcohort sampling.
Using All Available Covariate Data from Full Fohort Later, methods that seek
to utilize some of the phase 1 covariate information were proposed. Borgan et al. [2000]
considered a stratified sampling by a phase 1 variable which is a correlate of exposure,
to incorporate statum-specific ISW in the estimating equation. Stratum-specific ISW can
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be calculated using empirical sampling fraction within each stratum. He proposed three
different estimating equations by considering different types of weights. Simulation studies
suggested that the stratified estimator II with time-varying ISW, referred to as BII estimator
from herein, is the most efficient among the existing estimators. Kulich and Lin [2004]
established asymptotic theory for the BII type of estimators. In addition they developed a
class of weighted estimators which utilize all available covariate information from the full
cohort data. Proposed weighted estimators are 1) doubly weighted (DW) estimator and 2)
combined doubly weighted (CDW) estimator which involve general time-varying ISW. The
methods involve a modeling step for prediction of the values of each partially missing phase 2
variables, and is likely of greatest use when there are only 1 or 2 such variables. The authors
suggest to use CDW estimator in practice as DW estimator is efficient only if a model to
predict the phase 2 variables given all the phase 1 variables is correct. Numerical studies
indicated that the CDW estimator is more efficient then other existing estimators such as
Chen and Lo [1999], Borgan et al. [2000], and Chen et al. [2001]. The efficiency gain for the
phase 2 covariates depends on the ability of the first-phase data to predict the true values
of the partially missing variables. Later, Breslow et al. [2009a] and Breslow et al. [2009b]
considered calibration or estimation of ISW by making use of phase 1 covariate information.
Calibration method adjusts ISW to be as close as possible to the sampling weights subject
to a certain constraint. Estimation methods uses ISW as inverse of inclusion probabilities
estimated from a logistic regression model that predicts which cohort subjects are sampled
at phase 2. Simulation study and real data analysis reported by Breslow et al. [2009b]
showed that such adjustment on ISW can dramatically improve precision of the baseline
hazard ratios, which are estimated for baseline covariates, i.e., a part of phase 1 variables.
They also showed that the methods can improve precision for the phase 2 covariates when
their values may be imputed with reasonable accuracy for the non-subcohort controls.
In Chapter 4 we demonstrate how we can extend some of the aforementioned methods
might be extended to the causal setting and discuss why some of the methods might not be
useful to improve efficiency in the case-cohort MSCM analysis.
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Chapter 3
Marginal Structural Cox Models with Case-cohort Sampling
3.1 Introduction
Biomedical cohort studies are often conducted with the goal of assessing the effect of a
time-varying treatment (or exposure) on a survival time. In such studies there may exist
time-dependent covariates which are simultaneously (i) confounders and (ii) affected by
prior treatment. In the presence of time-varying confounders affected by prior treatment,
standard methods such as Cox regression modeling with time-varying covariates do not in
general yield consistent estimators of the causal effect of treatment Robins [1986, 1998];
Robins and Rotnitzky [1992]; Herna´n, Brumback and Robins [2001]. On the other hand,
marginal structural models (MSM) fit using inverse probability weighting can be employed
to obtain consistent estimators of the causal effect of a time-varying treatment on an out-
come of interest, even if there are time-varying confounders affected by prior treatment
Robins [1999].
For example, consider the Multicenter AIDS Cohort Study (MACS), an observational
study of HIV-positive homosexual men. Using data from MACS, Herna´n, Brumback and
Robins [2001] showed that (i) current CD4 count and Pneumocystis carinii pneumonia
(PCP) status were independent risk factors for death and were predictive of subsequent
treatment with zidovudine (AZT) and prophylaxis therapy, and (ii) prophylaxis therapy
was a protective risk factor for the development of PCP subsequently. Thus, to assess
the effect of AZT and prophylaxis therapy on mortality in MACS, a method is required
that can appropriately account for time-varying confounders affected by prior treatment (in
particular, PCP status). Applying standard (i.e., unweighted) Cox regression with time-
dependent covariates to the MACS data, Herna´n, Brumback and Robins [2001] reported an
estimated hazard ratio of 1.85 (95% CI 1.49, 2.30) for AZT users versus nonusers, suggesting
that treatment increases the risk of death in HIV-positive homosexual men, contrary to
results from randomized clinical trials. On the other hand, fitting a marginal structural
Cox model (MSCM) with inverse probability weighting yielded an estimated hazard ratio
for AZT of 0.67 (95% CI 0.46, 0.98), in agreement with results from randomized trials of
AZT. The difference in hazard ratio estimates between the unweighted Cox regression model
and the MSCM with inverse probability weighting is not surprising given the aforementioned
established results about the (in)consistency of the standard estimators in the presence of
time-varying confounders affected by prior treatment.
Recently, Cole et al. [2012] considered fitting MSCMs via inverse probability weighting
in the presence of case-cohort sampling. The case-cohort study design is a cost-efficient
approach to estimate treatment effects in large cohorts with low event rates, when treatment
or covariate information is expensive. The design entails randomly selecting a subcohort
from the entire cohort. Covariate information is then collected only from the random
subcohort and from individuals that are observed to experience an event (i.e., cases), saving
cost and effort relative to obtaining covariate information from the full cohort. In addition to
being cost efficient, the case-cohort design enjoys other benefits. For instance, the subcohort
can serve as a basis for real time covariate monitoring during the course of the study.
Also, because the subcohort is chosen randomly, survival times to different diseases can be
analyzed using the same subcohort Self and Prentice [1988].
In the presence of case-cohort sampling, Cole et al. [2012] considered estimating the
causal hazard ratio of a MSCM via inverse probability weighting. Simulation studies indi-
cated the estimator proposed by Cole et al. [2012] can perform well empirically, however no
formal justification for their estimator has been developed to date. Therefore, following Cole
et al. [2012], we consider estimating the causal hazard ratio of a MSCM via inverse probabil-
ity weighting in case-cohort studies and establish consistency and asymptotic normality for
the estimator that maximizes a weighted-pseudo-partial-likelihood (WPPL) under certain
regularity conditions.
The approach utilized in this paper entails standard counting process and martingale
theory. This formulation readily enables practical implementation of the methods using
existing survival analysis software. Framing the problem using counting processes may also
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be helpful in future work, e.g., in fitting MSCMs to data from nested case-control studies or
in the presence of competing risks. In the special situation that the subcohort equals the full
cohort, the proposed inverse probability weighted estimator is asymptotically equivalent to
the estimator in Robins [1999]. In this case our proof gives an alternative consistency and
normality proof to Robins [1999], who did not utilize the usual counting process framework.
We also derive a new variance estimator that arises from the counting process formulation
under both full and case-cohort settings. Empirical results presented in this paper indicate
that in certain scenarios the proposed variance estimator may be preferred to the so-called
“robust” variance estimator Lin and Ying [1993] employed in Cole et al. [2012].
The outline of the remainder of this paper is as follows. In §3.2, estimators of the
hazard ratio of a MSCM in the presence of case-cohort sampling are introduced, including
the estimator proposed by Cole et al. [2012]. Consistency and asymptotic normality are
established in §3.3 and §3.4, respectively. §3.5 explains how one can directly obtain the
proposed inverse probability weighted estimators using standard survival analysis software,
and presents a simulation study.
3.2 Marginal Structural Cox Model Estimators
3.2.1 Notation, Assumptions, and Model
Capital letters will represent random variables and lower case letters will represent values
of the random variables or constants. Consider an observational cohort study where the
outcome of interest is a survival time T , based on the time from study entry until some
particular outcome occurs. Throughout we assume T is continuous so that there are no
tied failure times between individuals. During the course of the study individuals may
dropout or discontinue participation in the study, such that T is not observed but rather
right censored at the last time the individual was under study. Suppose individuals may
or may not elect to receive treatment at various points of time during the study. Let Ai(t)
indicate whether subject i is on treatment at time t. If more than one treatment is available,
then Ai(t) is a vector of treatment indicator variables corresponding to the joint treatment
levels. In the sequel we assume Ai(t) is a p × 1 vector and treatment variation is irrelevant
VanderWeele [2009a]. The subscript i will often be suppressed, when there is no ambiguity,
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because we assume random vectors are drawn independently from a distribution common
to all subjects. Let L(t) denote a vector of covariates, such as CD4 count or PCP status,
at time t. Let L(0) represent baseline covariates. Overbars are used to represent history up
to and including time t such that A(t) = {A(u) ∶ 0 ≤ u ≤ t} and L(t) is defined analogously.
Assume that decisions related to treatment at t are made after obtaining the covariate
information at t, i.e., L(t) is temporally prior to A(t). For a case-cohort study, the time
varying covariates L(t) and treatment A(t) are by design observed only for the cases and
individuals in the random subcohort (while under study); L(t) and A(t) are missing for all
other individuals. Corresponding to the subcohort, let C˜ denote the set of indices of size
n˜ ≤ n that are randomly selected without replacement from the set {1, . . . , n} corresponding
to the entire cohort.
Let a denote a possible (static) treatment plan, i.e., a = {a(t) ∶ 0 ≤ t ≤ τ} where τ is the
study duration. Assume τ = 1 hereafter without loss of generality. Each possible value of
a can be interpreted as a prespecified treatment plan. Assuming a single treatment (i.e.,
p = 1), practical examples of a might be never treat (i.e., a(t) = 0 for all t ∈ [0,1]), treat
starting at a prespecified time t1 < 1 (i.e., a(t) = I{t ≥ t1} where I{⋅} is the usual indicator
function), treat from baseline (i.e., a(t) = 1 for all t ∈ [0,1]), etc. Define Ta to be a subject’s
potential failure time had (possibly contrary to what was observed in the actual study) the
subject been treated according to a. Let ⊥ denote statistical independence; e.g., A ⊥ B∣C
denotes A is independent of B given C. Assume
T = Ta ∀a such that a(t) = A(t) ∀t ≤ T, (3.1)
Ta ⊥ A(t)∣A(t−),L(t) ∀a, (3.2)
pr[A(t)∣A(t−),L(t)] > 0 ∀t ∈ [0,1] such that pr[A(t−),L(t)] > 0 (3.3)
which are referred to as the causal consistency, conditional exchangeability, and positivity
assumptions, respectively. Assumption (3.1) states that, in the absence of censoring, the
observed failure time T equals the potential failure time Ta for all treatment plans a consis-
tent (i.e., compatible) with the observed treatment up to time T . Assumption (3.2) states
that conditional on treatment and covariate histories, treatment at time t is independent of
the potential survival time under a (i.e., no unmeasured confounding). Assumption (3.3)
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states that the conditional probability of receiving any particular treatment is greater than
zero. Of these three assumptions, only (3.3) can be tested empirically. Sensitivity analysis
may be useful in assessing the robustness of inference drawn to violations of assumption
(3.2) Robins, Rotnitzky and D [1999].
Consider the MSCM
λTa(t) = λ0(t) exp{β′0f(a(t))}
where λTa(t) is the hazard of failure at time t if all individuals in the population had
followed treatment plan a through time t, λ0(t) is an unspecified baseline hazard function
corresponding to the hazard if all individuals had been untreated through time t, f(a(t))
is a specified function of treatment history up to time t, and β0 is an unknown parameter
vector. Hereafter, we consider the MSCM
λTa(t) = λ0(t)r{β′0a(t)} (3.4)
where for notational convenience we let r{⋅} = exp{⋅}. For example, if we are interested in
the causal effect of current AZT treatment on mortality of HIV-positive homosexual men,
then r(β0) is the ratio of the hazard of death at time t had all subjects in the population
alive at time t been exposed to AZT compared to had the subjects been unexposed at time
t. Note (3.4) focuses on the effect of current treatment status only; however, the results
presented below are valid for any specified f(a(t)).
In this paper the counting process framework is employed to study the large sample
behavior of estimators of β0. Note that all processes discussed hereafter refer to observed
processes. Let (Ω,F ,P) be a complete probability space and let {Ft ∶ t ∈ [0,1]} be an
increasing right-continuous family of sub σ-algebras of F consisting of failure times, co-
variates and treatment histories up to time t, and censoring histories up to time t+ for
all subjects in a cohort of size n. That is, the filtration with respect to the probability
space is the same as the usual filtration, except that treatment histories are now separated
from covariate histories. Let Ni(⋅) be a counting process adapted to Ft representing the
number of failures of subject i by time t such that dNi(t) indicates the number of events of
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subject i that occurred in [t, t + dt) for sufficiently small dt. Because failures are assumed
to occur in continuous time, we only allow jumps of size 1 and no simultaneous jumps can
occur in [t, t + dt). Let Ci(t) = 0 indicate that subject i remained uncensored prior to time
t and Ci(t) = 1 otherwise. The treatment process Ai(⋅) and the censoring process Ci(⋅)
are assumed to be piece-wise constant point processes with cadlag (right-continuous with
left-hand limits) step-function sample paths. The processes A(⋅) and C(⋅) are assumed to
have jumps that can occur at no more than a finite number of time points. Informally, this
means that all participants follow (approximately) the same visit schedule. This assump-
tion should be reasonable in studies with regularly scheduled follow-up visits (e.g., every six
months) and good study compliance. We refer to censoring as ignorable (or noninformative)
if the cause-specific hazard of being censored at t among subjects alive and uncensored does
not depend on the failure times Ta given prior treatment/covariate history A(t−) and L(t−)
(Herna´n, Brumback and Robins [2001]). Let Yi(t) = I{Ni(t) = Ci(t) = 0} denote whether
an individual is at-risk of being observed to fail at time t, having left-continuous sample
paths, and assume pr[Y (1) > 0] > 0.
3.2.2 Inverse Probability Weights
Suppose that we can correctly model the probability of receiving treatment at time t
given the past treatment history and covariate history. Then we can consistently estimate
the following weights
W T (t) =∏
k≤t
pr[A(k)∣A(k−)]
pr[A(k)∣A(k−),L(k)] , (3.5)
which will be referred to as inverse-probability-of-treatment-weights (IPTWs). Note that we
can consistently estimate the numerator probabilities in (4.2) based on sample proportions
because A(⋅) is assumed to have at most a finite number of jumps over the study period.
Under (3.2) to (3.3), in the absence of censoring, Robins [1999] showed that a consistent
estimator of the unknown parameter β0 in (3.4) can be obtained by fitting an ordinary time-
dependent Cox model with the contribution of subject i to the risk set at time t weighted
by estimates of (4.2). Informally we can think of the analysis via IPTWs as reweighting the
observed data set such that it has the same properties as a random sample, with respect to
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the measured confounders L, from a population where L(t) ⊥ A(t)∣A(t−) holds at time t.
The weighted study population is sometimes called a pseudo-population.
Dropout (i.e., right censoring) may introduce selection bias if dropout is associated with
exposure and dropout is associated with the outcome. In the presence of such censoring, we
still can obtain a consistent estimator of β0 by fitting the ordinary Cox model but weighting
a subject alive and uncensored at time t by estimates of W T (t) ×WC(t), where
WC(t) =∏
k≤t
pr[C(k) = 0∣C(k−) = 0,A(k−)]
pr[C(k) = 0∣C(k−) = 0,A(k−),L(k)] , (3.6)
under the assumption of no unmeasured confounders for censoring, an analogous assump-
tion to (3.3) for censoring, and assuming that we can correctly model the denominator
probabilities in (3.6) Robins [1999]. Here the weighted study population can be thought
of as a pseudo-population in which there is no confounding due to measured covariates
or selection bias due to censoring. In §3.2.3, we will make use of the (stabilized) weights
defined by W (t) ≡ W T (t) ×WC(t) after modifying (4.2) by adding C(k) = 0 to the condi-
tioning events in both the numerator and the denominator Herna´n, Brumback and Robins
[2000]. Hereafter W (t) will be referred to as inverse-probability-weights (IPWs). Note that
(4.2) and (3.6) are finite products. In addition, (3.3) ensures non-zero probabilities in the
denominators of (4.2) and (3.6) and hence the IPWs at all t are bounded.
Results presented in this article are not limited to a specific form of the weights W (t).
The proposed methods are applicable to different inverse probability weighting analysis
provided that the IPWs (or IPTWs in the absence of censoring) are bounded, such as when
truncated [Cole and Herna´n, 2008] and normalized [Xiao, Abrahamowicz and Moodie, 2010]
weights are employed. Under the assumption of finite support of the treatment and censor-
ing processes, unstabilized weights [Herna´n, Brumback and Robins, 2001] are also bounded.
However, unstabilized weights are known to be highly variable and are by design mono-
tone increasing functions of t. Other weights such as stabilized, truncated, and normalized
weights are generally recommended in practice as they lead to more efficient estimators of
the causal treatment effect.
We now briefly describe estimation of the random weights W (t), denoted by Wˆ (t).
One may specify a pooled logistic model (treating each person-visit as an observation) to
25
estimate the probability in denominators of (4.2) and (3.6) at each time (for example, at
each visit), then plug in the estimated probabilities to (4.2) and (3.6) Herna´n, Brumback
and Robins [2000, 2001]. We assume throughout that the model to estimate denominator
probabilities in the IPWs is correctly specified. In practice, investigators may want to
explore the sensitivity of the regression coefficients to different model specifications for
estimating the weights.
3.2.3 Weighted-Psuedo-Partial-Likelihood
In this section we consider two weighted-pseudo-partial-likelihoods (WPPLs) which form
the basis for obtaining consistent estimators of β0 in the presence of case-cohort sampling.
TheWPPLs are formed by weighting individual contributions to the usual partial likelihoods
by Wi(t) assuming that Wi(t) is known. In the case-cohort setting, we consider a set of
individuals C˜ of size n˜ ≤ n that is randomly selected without replacement from the entire
cohort {1, . . . , n}.
The log-WPPL created by individual-time-specific weights at time t under the full cohort
setting is given by
l(β, t;W ) = (3.7)
n
∑
i=1
∫
t
0
Wi(u)[β′Ai(u) − log
n
∑
l=1
Wl(u)Yl(u)r{β′Al(u)}]dNi(u),
which is motivated by the weighted estimating equations proposed by Robins [1993].
The log-WPPL in the case-cohort setting is
l˜(β, t;W ) = (3.8)
n
∑
i=1
∫
t
0
Wi(u)[β′Ai(u) − log∑
l∈C˜
Wl(u)Yl(u)r{β′Al(u)}]dNi(u).
Note (3.8) is slightly different from the log-WPPL proposed by Cole et al. [2012], which is
l∗(β, t;W ) = (3.9)
n
∑
i=1
∫
t
0
Wi(u)[β′Ai(u) − log ∑
l∈C˜∪{i}
Wl(u)Yl(u)r{β′Al(u)}]dNi(u).
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The log-WPPLs (3.8) and (3.9) differ only in whether a case outside the subcohort C˜
contributes to the risk set. In the absence of weights, i.e., Wi(u) = 1 for all i and u, (3.8)
reduces to the log-likelihood considered by Self and Prentice [1988] and (3.9) reduces to the
log-likelihood considered by Prentice [1986b]. Estimators that maximize (3.8) or (3.9) will
be shown to converge in probability to β0.
Note that under (3.1) each (observed) counting process Ni(⋅)(i = 1, ..., n) can be uniquely
decomposed into the sum of its intensity process λi and a local square integrable martingale
Mi, i.e.,
Ni(t) = ∫
t
0
λi(u)du +Mi(t), t ∈ [0,1], (3.10)
where the intensity process is given by
λi(t) = Yi(t)r{β′0Ai(t)}λ0(t), (3.11)
which embodies the same parameters as in (3.4).
Define βˆ, β˜, and β∗ to be solutions to ∂l(β,1;Wˆ )/∂β = 0, ∂l˜(β,1;Wˆ )/∂β = 0, and
∂l∗(β,1;Wˆ )/∂β = 0, respectively. Consider the following processes
X(β, t;W ) = n−1{l(β, t;W ) − l(β0, t;W )} (3.12)
= n−1
n
∑
i=1
∫
t
0
Wi(u)[(β − β0)′Ai(u)
− log ∑
n
l=1Wl(u)Yl(u)r{β′Al(u)}
∑nl=1Wl(u)Yl(u)r{β′0Al(u)}
]dNi(u),
X˜(β, t;W ) = n−1{l˜(β, t;W ) − l˜(β0, t;W )} (3.13)
= n−1 ∑
i∈C
∫
t
0
Wi(u)[(β − β0)′Ai(u)
− log ∑l∈C˜Wl(u)Yl(u)r{β
′Al(u)}
∑l∈C˜Wl(u)Yl(u)r{β′0Al(u)}
]dNi(u)
corresponding to (3.7) and (3.8) respectively. We will first show that X(β, t;Wˆ ) and (3.12)
are asymptotically equivalent, and so are X˜(β, t;Wˆ ) and (3.13). Thus, further technical
developments will be made based on (3.12) and (3.13). We then show that (3.12) and
(3.13) at t = 1 converge in probability to functions of β which are concave with a unique
27
maximum β0 under certain conditions. Using the same argument as in Andersen and Gill
[1982], it follows that βˆ →p β0 and β˜ →p β0. That β
∗
→p β0 can be shown analogously by
using X∗(β, t;W ) = n−1{l∗(β, t;W ) − l∗(β0, t;W )}. Asymptotic normality of βˆ and β˜ will
be shown via asymptotic normality of score statistics corresponding to (3.7) and (3.8).
3.3 Consistency
For a p × 1 column vector c, let c⊗0 = 1, c⊗1 = c, and c⊗2 = cc′, ci denote i-th element
of c, and cij denote (i, j) element of c⊗2. Norms are defined by ∣∣c⊗2∣∣ = supi,j ∣cij ∣, ∣∣c∣∣ =
supi ∣ci∣, and ∣c∣ = (∑ c2i )1/2 = (c′c)1/2. Also let r(0){β′A(t)} = r{β′A(t)}, r(1){β′A(t)} =
A(t)r{β′A(t)}, and r(2){β′A(t)} = A(t)⊗2r{β′A(t)}.
CONDITIONS.
A (Uniform consistency of estimated weights)
sup
i∈{1,...,n}
t∈[0,1]
∣Wˆi(t) −Wi(t)∣ ≡MWˆ →p 0.
Along with the assumption of no misspecification of the model used to estimate denom-
inator probabilities in W (⋅), the finite number of jumps assumption on the treatment and
censoring processes are sufficient for this condition to hold. From a practical point of view,
having a finite number of time points when treatment status can change or when censoring
might occur may be reasonable to assume in many settings. For instance, studies often
have planned visits at finite discrete intervals when a patient may have treatment altered.
Similarly, the censoring time for a subject is often assumed to be the last observed visit
time before the subject became lost-to-follow-up.
B (Stability of weights) Individual time-specific weights Wi(t) and the corresponding es-
timators Wˆi(t) are strictly positive and bounded, i.e., there exist positive real numbers
M1 and M2 such that
sup
i∈{1,...,n}
t∈[0,1]
Wi(t) ≤M1, and sup
i∈{1,...,n}
t∈[0,1]
Wˆi(t) ≤M2.
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Note that Wˆ (⋅) and W (⋅) are assumed to be predictable with respect to the filtration
Ft because weights are determined by predictable processes: A(⋅), L(⋅), and their histories.
All weights discussed in §3.2.2 satisfy the conditions A and B under any circumstances,
except the unstabilized weights. Unstabilized weights satisfy conditions A and B under the
assumption of finite support of A(⋅) and C(⋅).
C (Finite interval) ∫ 10 λ0(t)dt <∞
D (Asymptotic stability)
(i) There exists a neighborhood B0 of β0 and functions s(0), s(1), and s(2) defined on
B0 × [0,1] such that
sup
β∈B0
t∈[0,1]
∣∣S(j)(β, t) − s(j)(β, t)∣∣ →p 0, j = 0,1,2
where S(j)(β, t) = n−1∑ni=1 Yi(t)r(j){β′Ai(t)} for j = 0,1,2, which are the same
quantities as given in Andersen and Gill [1982] with covariates Zi(t) being replaced
by the treatment process Ai(t).
(ii) Let S
(j)
W(k)
= n−1∑ni=1Wi(t)kYi(t)r(j){β′Ai(t)} for j = 0,1,2 and k = 1,2. There
exists a neighborhood B of β0, B ⊆ B0, and functions s(j)W(k) defined on B×[0,1] such
that
sup
β∈B
t∈[0,1]
∣∣S(j)W(k)(β, t) − s
(j)
W(k)
(β, t)∣∣ →p 0, j = 0,1,2;k = 1,2
(iii) S
(0)
W(1)
(β0, t) converges in distribution to a mean zero Gaussian random variable
uniformly in t, i.e.,
n1/2{S(0)
W(1)
(β0, t) − s(0)W(1)(β0, t)} →d N(0, σ2(t)), uniformly in t ∈ [0,1],
for some σ2(t).
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E (Lindeberg condition) For any ǫ > 0, j = 1, ..., p
n−1∫
1
0
n
∑
i=1
Wi(u)2[Aij(u) −EW(1)(β0, u)j]2Yi(u)r{β′0Ai(u)}
× I{n−1/2Wi(u)∣Aij(u) −EW(1)(β0, u)j ∣ > ǫ}λ0(u)du →p 0
where E = S(1)/S(0), EW(k) = S
(1)
W(k)
/S(0)W(k), and in general cj denotes the jth component
of any p × 1 vector c.
If the treatment process A(⋅) is bounded (as assumed throughout this paper) and Con-
ditions B and F are satisfied, then Condition E holds trivially.
F (Asymptotic regularity conditions) s(j)(β, t) and s(j)W(k)(β, t) are continuous functions of
β ∈ B uniformly in t ∈ [0,1] that are bounded on B × [0,1] for j = 0,1,2 and k = 1,2. For
all (β, t) ∈ B × [0,1], define
s(m+1)(β, t) = ∂s
(m)(β, t)
∂β
, s
(m+1)
W(k)
(β, t) =
∂s
(m)
W(k)
(β, t)
∂β
for m = 0,1, and e = s(1)/s(0), eW(k) = s
(1)
W(k)
/s(0)W(k), v = s
(2)/s(0) − e⊗2, vW(k) = s(2)W(k)/s
(0)
W(k)
−
e⊗2
W(k)
, and VW(k) = S
(2)
W(k)
/S(0)
W(k)
− E⊗2
W(k)
for k = 1,2. Assume that s(0) and s
(0)
W(k)
are
bounded away from zero and the matrices
Σ = ∫
1
0
v(β0, t)s(0)(β0, t)λ0(t)dt, and
ΣW(k) = ∫
1
0
vW(k)(β0, t)s
(0)
W(k)
(β0, t)λ0(t)dt
are positive definite.
Note eW(k) can be interpreted as the weighted average of a treatment function with the
weights taking an exponential form. The positive definite condition on Σ in Andersen and
Gill [1982] can easily be extended to the ΣW(k) assumingW (t) are bounded away from zero
on t ∈ [0,1].
Conditions A-F are sufficient to prove consistency of βˆ. To prove the consistency of
β˜ and β∗, the following additional condition is required to ensure asymptotic behavior of
certain subcohort averages.
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G (Stability of subcohort average) Define
S˜
(j)
W(k)
(β, t) = n˜−1∑
i∈C˜
Wi(t)kYi(t)r(j){β′Ai(t)},
and E˜W(k) = S˜
(1)
W(k)
/S˜(0)
W(k)
for j = 0,1,2 and k = 1,2.
(i) (Nontrivial subcohort) n˜n−1 →p α for some α ∈ (0,1].
(ii) (Asymptotic normality of subcohort averages at β0) For any ǫ > 0
sup
t∈[0,1]
n−1
n
∑
i=1
Wi(t)2Yi(t)r{β′0Ai(t)}2I{n−1/2Wi(t)Yi(t)r{β′0Ai(t)} > ǫ}→p 0,
sup
t∈[0,1]
n−1
n
∑
i=1
Wi(t)2Yi(t)∣∣r(1){β′0Ai(t)}∣∣2I{n−1/2Wi(t)Yi(t)∣∣r(1){β′0Ai(t)}∣∣ > ǫ}
→p 0,
and the sequences of distributions of n1/2{E˜(β0, t) − E(β0, t)} are tight on the
product space of cadlag functions equipped with the product Skorohod topology
and so are n1/2{E˜W(1)(β0, t) −EW(1)(β0, t)}.
(iii) (Asymptotic stability and regularity of covariance function) There exists a neigh-
borhood B of β0 and functions q(j)(β, t, u) for j = 0,1,2, defined on B × [0,1]2 such
that q(j)(β, t, u) are continuous functions of β ∈ B uniformly in (t, u) ∈ [0,1]2, the
q(j) are bounded on B × [0,1]2 and
sup
β∈B
(t,u)∈[0,1]2
∣∣Q(j)(β, t, u) − q(j)(β, t, u)∣∣ →p 0, j = 0,1,2, where
Q(0)(β, t, u) = n−1
n
∑
i=1
Wi(t)Yi(t)r{β′0Ai(t)}Wi(u)Yi(u)r{β′0Ai(u)},
Q(1)(β, t, u) = n−1
n
∑
i=1
Wi(t)Yi(t)r(1){β′0Ai(t)}Wi(u)Yi(u)r(1){β′0Ai(u)}′,
Q(2)(β, t, u) = n−1
n
∑
i=1
Wi(t)Yi(t)r{β′0Ai(t)}Wi(u)Yi(u)r(1){β′0Ai(u)}.
Moreover, supn≥1 E[Q(j)(β, t, u)] for j = 0,1,2 are bounded sequences where E
denote expectation.
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(iv) (Asymptotic stability of subcohort averages) Let Q˜(j)(β, t, u) be covariance func-
tions based on subcohort members i = 1, ..., n˜. Then
sup
β∈B
t∈[0,1]
∣∣S˜(0)
W(k)
(β, t) − s(0)
W(k)
(β, t)∣∣ →p 0 k = 1,2,
i.e., the subcohort average converges to the mean of the full cohort, and
sup
β∈B
(t,u)∈[0,1]2
∣∣Q˜(j)(β, t, u) − q(j)(β, t, u)∣∣ →p 0, j = 0,1,2.
i.e., the subcohort covariance functions converge in probability to the full cohort
covariance functions. In addition, S˜
(0)
W(1)
(β0, ⋅) converges in distribution to a mean
zero Gaussian random variable uniformly in t, i.e.,
n1/2{S˜(0)
W(1)
(β0, t) − s(0)W(1)(β0, t)} →d N(0, σ˜2(t)), uniformly in t ∈ [0,1]
for some σ˜2(t).
Condition G is the same as condition G in Self and Prentice [1988], incorporating
individual-specific time-varying weights Wi(t)(i = 1, ..., n).
Theorem 3.3.1. (Consistency of βˆ under full cohort) Under conditions A-F, βˆ →p β0.
Proof. Consider the process X(β, t;W ) given by (3.12) and its compensator counterpart
K(β, t;W ) which is given by
K(β, t;W ) = n−1
n
∑
i=1
∫
t
0
Wi(u)[(β − β0)′Ai(u) − log {
S
(0)
W(1)
(β,u)
S
(0)
W(1)
(β0, u)
}]λi(u)du
where λi(t) is given as in (3.11). We start by showing that
∣{X(β, t;Wˆ ) −K(β, t;Wˆ )} − {X(β, t;W ) −K(β, t;W )}∣ →p 0 (3.14)
so that we can consider the asymptotic behavior of X(β, t;W ) − K(β, t;W ) instead of
X(β, t;Wˆ ) − K(β, t;Wˆ ) to prove consistency of βˆ. To prove (3.14), first note the term
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∣{X(β, t;Wˆ ) −K(β, t;Wˆ )} − {X(β, t;W ) −K(β, t;W )}∣ in (3.14) equals
∣n−1
n
∑
i=1
∫
1
0
[Wˆi(u)(β − β0)′Ai(u) − Wˆi(u) log {
S
(0)
Wˆ(1)
(β,u)
S
(0)
Wˆ(1)
(β0, u)
}]dMi(u)
− n−1
n
∑
i=1
∫
1
0
[Wi(u)(β − β0)′Ai(u) −Wi(u) log {
S
(0)
W(1)
(β,u)
S
(0)
W(1)
(β0, u)
}]dMi(u)∣.
Replacing Wi(u) in front of log{S(0)W(1)(β,u)/S
(0)
W(1)
(β0, u)} with Wi(u)− Wˆi(u)+ Wˆi(u) and
rearranging terms yields
∣n−1
n
∑
i=1
∫
1
0
{Wˆi(u) −Wi(u)}(β − β0)′Ai(u)dMi(u) (3.15)
− n−1
n
∑
i=1
∫
1
0
{Wˆi(u) −Wi(u)} log {
S
(0)
W(1)
(β,u)
S
(0)
W(1)
(β0, u)
}dMi(u)
− n−1
n
∑
i=1
∫
1
0
Wˆi(u) log {
S
(0)
Wˆ(1)
(β,u)
S
(0)
Wˆ(1)
(β0, u)
/
S
(0)
W(1)
(β,u)
S
(0)
W(1)
(β0, u)
}dMi(u)∣.
Each term in (3.15) is a local square integrable martingale since g(Wi(⋅),Ai(⋅)) is predictable
for any continuous function g(⋅) due to predictableness of Wi(⋅) and Ai(⋅). Because Wˆi(⋅)
is also bounded and predictable, the same argument can be made for g1(Wˆi(⋅),Ai(⋅)) and
g2(Wi(⋅), Wˆi(⋅)) for any continuous functions g1(⋅) and g2(⋅). We will show that the variance
process of each martingale in (3.15) converges in probability to zero, thus proving (3.14).
Let B1(β, t) be the variance process of the first martingale in (3.15). Then
B1(β, t) = n−2
n
∑
i=1
∫
t
0
{Wˆi(u) −Wi(u)}2(β − β0)′Ai(u)⊗2(β − β0)λi(u)du
= n−2
n
∑
i=1
∫
t
0
{Wˆi(u) −Wi(u)}2(β − β0)′Yi(u)r(2){β′0Ai(u)}(β − β0)λ0(u)du
≤ n−1∫
t
0
M
2
Wˆ
(β − β0)′[n−1
n
∑
i=1
Yi(u)r(2){β′0Ai(u)}](β − β0)λ0(u)du
= n−1M2
Wˆ ∫
t
0
(β − β0)′S(2)(β0, u)(β − β0)λ0(u)du
which converges in probability to zero due to conditions A, B, D, and F. The second equal-
ity is owing to (3.11), and the inequality comes from replacing {Wˆi(u) −Wi(u)}2 by its
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supremum value M2
Wˆ
. Let B2(β, t) be the variance process of the second martingale term
in (3.15). Then
B2(β, t) =n−2
n
∑
i=1
∫
t
0
{Wˆi(u) −Wi(u)}
2
{logS(0)
W(1)
(β,u) − logS(0)
W(1)
(β0, u)}
2
λi(u)du
≤n−1∫
t
0
M
2
Wˆ
{logS(0)W(1)(β,u) − logS
(0)
W(1)
(β0, u)}
2
S(0)(β0, u)λ0(u)du
which converges to zero due to conditions A, B, D, and F. Lastly, let the variance of the
third martingale term in (3.15) be B3(β, t). Then
B3(β, t) = n−2
n
∑
i=1
∫
t
0
Wˆi(u)2[{logS(0)
Wˆ(1)
(β,u) − logS(0)
W(1)
(β,u)}
− {logS(0)
Wˆ(1)
(β0, u) − logS(0)W(1)(β0, u)}]
2
λi(u)du
= n−1∫
1
0
[{logS(0)
Wˆ(1)
(β,u) − logS(0)
W(1)
(β,u)}
− {logS(0)
Wˆ(1)
(β0, u) − logS(0)W(1)(β0, u)}]
2
S
(0)
Wˆ(2)
(β0, u)λ0(u)du
≤ n−1∫
1
0
[ sup
β,u
∣ logS(0)
Wˆ(1)
(β,u) − logS(0)
W(1)
(β,u)∣2
+ 2 sup
β,u
∣ logS(0)
Wˆ(1)
(β,u) − logS(0)
W(1)
(β,u)∣ sup
u
∣ logS(0)
Wˆ(1)
(β0, u) − logS(0)W(1)(β0, u)∣
+ sup
u
∣ logS(0)
Wˆ(1)
(β0, u) − logS(0)W(1)(β0, u)∣2]S
(0)
Wˆ(2)
(β0, u)λ0(u)du
which converges in probability to zero due to conditions A, B, D, F, and by the continuous
mapping theorem. It follows that X(β, t;Wˆ ) −K(β, t;Wˆ ) and X(β, t;W ) −K(β, t;W ) in
(3.14) are asymptotically equivalent processes. Thereby we proceed to describe asymptotic
behavior of the process X(β, t;W ) − K(β, t;W ). Hereafter for notation convenience we
suppress W when writing X(β, t;W ) and K(β, t;W ).
Now consider X(β, t) −K(β, t), which equals to
n−1
n
∑
i=1
∫
t
0
Wi(u)[(β − β0)′Ai(u) − log {
S
(0)
W(1)
(β,u)
S
(0)
W(1)
(β0, u)
}]dMi(u),
which is a martingale. After some calculation, it can be shown that its variance process
B(β, t) can be simplified as
34
n−1∫
1
0
[(β − β0)′S(2)W(2)(β0, u)(β − β0) (3.16)
− 2(β − β0)′S(1)W(2)(β0, u) log {
S
(0)
W(1)
(β,u)
S
(0)
W(1)
(β0, u)
}
+
⎧⎪⎪⎪⎨⎪⎪⎪⎩
log (
S
(0)
W(1)
(β,u)
S
(0)
W(1)
(β0, u)
)
⎫⎪⎪⎪⎬⎪⎪⎪⎭
2
S
(0)
W(2)
(β0, u)]λ0(u)du
where each term inside the integral converges in probability to a function of finite quantities
s
(j)
W(k)
on β ∈ B in view of conditions D and F. Therefore, (3.16) converges in probability to
zero. It follows that X(β, t) and K(β, t) converge in probability to the same limit by the
Lenglart inequality, i.e., that pr[supt,β ∣∣X(β, t) −K(β, t) > η∣∣] ≤ δ/η2 + pr[B(β,1) > δ] for
all δ, η > 0.
Therefore, to investigate asymptotic properties of X(β,1), consider asymptotic properties
of K(β,1) instead:
K(β,1) →p ∫
1
0
[(β − β0)′s(1)W(1)(β0, u) − log {
s
(0)
W(1)
(β,u)
s
(0)
W(1)
(β0, u)
}s(0)
W(1)
(β0, u)]λ0(u)du
by (3.11). Let Kl(β,1) be the limiting quantity shown in the above. Then
∂Kl(β,1)
∂β
= ∫
1
0
[s(1)
W(1)
(β0, u) −
s
(1)
W(1)
(β,u)
s
(0)
W(1)
(β,u)
s
(0)
W(1)
(β0, u)]λ0(u)du
which is zero at β = β0. In addition, ∂
2Kl(β,1)/∂β2 is
−∫
1
0
[
s
(2)
W(1)
(β,u)s(0)W(1)(β,u) − s
(1)
W(1)
(β,u)⊗2
s
(0)
W(1)
(β,u)2
]s(0)
W(1)
(β0, u)λ0(u)du
= −∫
1
0
vW(1)(β,u)s
(0)
W(1)
(β0, u)λ0(u)du
which equals to −ΣW(1) and is negative definite when β = β0 based on condition F. Therefore
K(β,1) converges to a concave function having unique maximum at β0. This enables us to
make use of Theorem II.1 in Andersen and Gill [1982] that proves in probability convergence
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of X(β,1) to the same concave function of β as does K(β,1), with a unique maximum at
β = β0. Then βˆ →p β0.
Consistency of β˜ can be shown using similar arguments as in Theorem 3.3.1. It can
immediately be seen that X˜(β, t;Wˆ ) is asymptotically equivalent to X˜(β, t;W ) by condition
A. Therefore, we can show that X˜(β, t) converges in probability to K(β, t) so that the same
argument as in the proof of Theorem 3.3.1 can be made. In particular, ∣X˜(β, t) −K(β, t)∣
will be decomposed into two terms, ∣X(β, t) − K(β, t)∣ plus a term that will converge in
probability to zero.
Theorem 3.3.2. (Consistency of β˜ under the case-cohort) Under conditions A-G, β˜ →p β0.
Proof. First, ∣X˜(β, t) −K(β, t)∣ can be rewritten as
∣n−1∫
t
0
n
∑
i=1
Wi(u)(β − β0)′Ai(u)dMi(u)
− n−1∫
t
0
n
∑
i=1
Wi(u) log {
S˜
(0)
W(1)
(β,u)
S˜
(0)
W(1)
(β0, u)
}dNi(u)
+ n−1∫
t
0
n
∑
i=1
Wi(u) log {
S
(0)
W(1)
(β,u)
S
(0)
W(1)
(β0, u)
}λi(u)du∣
≤∣X(β, t) −K(β, t)∣
+ ∣n−1∫
t
0
n
∑
i=1
Wi(u){ log (
S˜
(0)
W(1)
(β,u)
S˜
(0)
W(1)
(β0, u)
) − log (
S
(0)
W(1)
(β,u)
S
(0)
W(1)
(β0, u)
)}dNi(u)∣.
We have shown that ∣X(β, t) −K(β, t)∣ →p 0. The remaining term can be decomposed as
∣n−1∫
t
0
[
n
∑
i=1
Wi(u){ log (
S˜
(0)
W(1)
(β,u)
S˜
(0)
W(1)
(β0, u)
) − log (
S
(0)
W(1)
(β,u)
S
(0)
W(1)
(β0, u)
)}dMi(u)] (3.17)
+ n−1∫
t
0
n
∑
i=1
[Wi(u){ log (
S˜
(0)
W(1)
(β,u)
S˜
(0)
W(1)
(β0, u)
) − log (
S
(0)
W(1)
(β,u)
S
(0)
W(1)
(β0, u)
)}λi(u)du]∣.
Then the second term in (3.17) can easily be shown to converge in probability to zero in
view of conditions C, D, F and G(iv). Also the martingale in (3.17) converges in probability
to zero because its variance process is
36
∣n−2∫
t
0
n
∑
i=1
Wi(u)2[{ log S˜(0)W(1)(β,u) − logS
(0)
W(1)
(β,u)}
− { log S˜(0)
W(1)
(β0, u) − logS(0)W(1)(β0, u)}]
2
λi(u)du∣
≤∣n−1∫
t
0
[ sup
β,u
∣ log S˜(0)W(1)(β,u) − logS
(0)
W(1)
(β,u)∣
+ sup
u
∣ log S˜(0)W(1)(β0, u) − logS
(0)
W(1)
(β0, u)∣]
2
S
(0)
W(2)
(β0, u)λ0(u)du∣
which converges in probability to zero, again by (3.11) with conditions C, D, F and G(iv).
Note that sum of supremums in the integrand (which can be taken outside the integral)
converges in probability to zero by conditions D and G(iv).
It is straightforward to show that the estimator based on (3.9) converges in probability
to the same limit as β˜. An individual case’s contribution to C˜ at its failure time (which
is weighted by its IPWs) is asymptotically negligible in the sense that IPWs are bounded
at all times and weighted subcohort averages are asymptotically stable (conditions B and
G(iv)). This is formally stated in the following Theorem.
Theorem 3.3.3. Under conditions A-G, β˜ − β∗ →p 0.
Proof. We sketch a proof of Theorem 3.3.3. Consider the following process
X∗(β, t) = n−1{l∗(β, t) − l∗(β0, t)}.
Then X∗(β, t) = n−1{l˜(β, t)− l˜(β0, t)}+op(1) because n−1l∗(β, t) = n−1l˜(β, t)+op(1). There-
fore, X∗(β, t) and X˜(β, t) are asymptotically equivalent processes and we can repeat the
proof of Theorem 3.3.2 using X∗(β, t) instead of X˜(β, t).
3.4 Asymptotic Normality
To prove asymptotic normality of β˜, we first prove asymptotic normality of the score
process of the log WPPL for the full cohort setting.
Theorem 3.4.1. (Asymptotic normality of the full cohort MSCM score statistic) Under
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conditions A-F,
n−1/2U(β0,1) →d N(0,ΣU )
where ΣU = ΣW(2) +∆W(1),W(2) with
∆W(1),W(2) = ∫
1
0
{eW(2)(β0, u) − eW(1)(β0, u)}⊗2s(0)W(2)(β0, u)λ0(u)du. (3.18)
Proof. We will refer to the score process under the full cohort setting as the full cohort
MSCM score process. Let U(β0, t) be the full cohort MSCM score process at time t. Then
n−1/2U(β0, t) = n−1/2∂l(β, t)/∂β∣
β=β0
(3.19)
= n−1/2
n
∑
i=1
∫
t
0
Wi(u)[Ai(u) −
S
(1)
W(1)
(β0, u)
S
(0)
W(1)
(β0, u)
]dNi(u)
= n−1/2
n
∑
i=1
∫
t
0
Wi(u)[Ai(u) −EW(1)(β0, u)]dMi(u)
The third equality follows from (3.10) and the fact that
n−1/2
n
∑
i=1
∫
t
0
Wi(u)[Ai(u) −EW(1)(β0, u)]λi(u)du = 0 (3.20)
based on (3.11). Set Hi(t) = n−1/2Wi(t)[Ai(t)−EW(1)(β0, t)] for i = 1, ..., n. This is a locally
bounded predictable process. Therefore, (3.19) is a local square integrable martingale.
To apply the martingale central limit theorem to the local square integrable martingale,
we show that n−1/2U(β0,1) = ∑ni=1 ∫ 10 Hi(t)dMi(t) satisfies (i) ∫ 10 ∑ni=1Hij(t)2I{∣Hij(t)∣ >
ǫ}λi(t)dt →p 0 for any ǫ > 0 (the Lindeberg condition), and that (ii) variance process
of (3.19) evaluated at t = 1 converges in probability to a finite quantity. Condition (i) is
satisfied because of condition E. To see if condition (ii) is satisfied, consider variance process
of n−1/2U(β0,1),
n
∑
i=1
∫
1
0
Hi(u)⊗2λi(u)du
=∫
1
0
n−1
n
∑
i=1
Wi(u)2[Ai(u) −EW(1)(β0, u)]
⊗2
λi(u)du
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=∫
1
0
n−1
n
∑
i=1
[Wi(u)2Yi(u)r(2){β′0Ai(u)} − 2Wi(u)2Yi(u)r(1){β′0Ai(u)}{EW(1)(β0, u)}′
+Wi(u)2Yi(u)r{β′0Ai(u)}EW(1)(β0, u)⊗2]λ0(u)du
=∫
1
0
[S(2)W(2)(β0, u) − 2S
(1)
W(2)
(β0, u){EW(1)(β0, u)}′ + S(0)W(2)(β0, u)EW(1)(β0, u)⊗2]λ0(u)du
=∫
1
0
[
S
(2)
W(2)
(β0, u)
S
(0)
W(2)
(β0, u)
− 2
S
(1)
W(2)
(β0, u)
S
(0)
W(2)
(β0, u)
{
S
(1)
W(1)
(β0, u)
S
(0)
W(1)
(β0, u)
}
′ + {
S
(1)
W(1)
(β0, u)
S
(0)
W(1)
(β0, u)
}
⊗2
]S(0)W(2)(β0, u)λ0(u)du
=∫
1
0
[{
S
(2)
W(2)
(β0, u)
S
(0)
W(2)
(β0, u)
− (
S
(1)
W(2)
(β0, u)
S
(0)
W(2)
(β0, u)
)
⊗2
} + {(
S
(1)
W(2)
(β0, u)
S
(0)
W(2)
(β0, u)
)
⊗2
− 2
S
(1)
W(2)
(β0, u)
S
(0)
W(2)
(β0, u)
(
S
(1)
W(1)
(β0, u)
S
(0)
W(1)
(β0, u)
)
′ + (
S
(1)
W(1)
(β0, u)
S
(0)
W(1)
(β0, u)
)
⊗2
}]S(0)
W(2)
(β0, u)λ0(u)du
=∫
1
0
[VW(2)(β0, u) + {EW(2)(β0, u) −EW(1)(β0, u)}⊗2]S(0)W(2)(β0, u)λ0(u)du.
Finally we can see that the variance process of n−1/2U(β0,1) converges in probability to
ΣW(2) +∆W(1),W(2) ≡ ΣU (3.21)
where ∆W(1),W(2) is given in (3.18). Based on conditions C and F, (3.21) is a finite quantity.
Therefore, the full cohort MSCM score statistic converges in distribution to a Gaussian
process with mean zero and the limiting covariance process ΣU by the martingale central
limit theorem. When Wi(t) ≡ 1 for all i = 1, ..., n and t ∈ [0,1], ∆W(1),W(2) becomes zero
and (3.21) equals to Σ which is the asymptotic variance of the score process under the full
cohort.
The score process corresponding to (3.8), which will be referred to as case-cohort MSCM
score process, is defined by
n−1/2U˜(β0, t) =n−1/2∂l˜(β, t)/∂β∣
β=β0
(3.22)
=n−1/2
n
∑
i=1
∫
t
0
Wi(u)[Ai(u) − E˜W(1)(β0, u)]dNi(u).
Replacing E˜W(1)(β0, u) in (3.22) with EW(1)(β0, u) + E˜W(1)(β0, u) −EW(1)(β0, u), we obtain
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n−1/2U˜(β0, t) = n−1/2
n
∑
i=1
∫
t
0
Wi(u)[Ai(u) −EW(1)(β0, u)]dMi(u) (3.23)
− n1/2∫
t
0
[E˜W(1)(β0, u) −EW(1)(β0, u)]S(0)W(1)(β0, u)λ0(u)du
− n−1/2
n
∑
i=1
∫
t
0
Wi(u)[E˜W(1)(β0, u) −EW(1)(β0, u)]dMi(u).
(3.23) is equivalent to
n−1/2
n
∑
i=1
∫
t
0
Wi(u)[Ai(u) −EW(1)(β0, u)]dMi(u) (3.24)
− ∫
t
0
Dn(u)λ0(u)du
− ∫
t
0
Dn(u){S(0)W(1)(β0, u)/S˜
(0)
W(1)
(β0, u) − 1}λ0(u)du
+ ∫
t
0
n1/2{EW(1)(β0, u) − eW(1)(β0, u)}{S˜(0)W(1)(β0, u) − S
(0)
W(1)
(β0, u)}
× S(0)
W(1)
(β0, u)/S˜(0)W(1)(β0, u)λ0(u)du
− n−1/2
n
∑
i=1
∫
t
0
Wi(u)[E˜W(1)(β0, u) −EW(1)(β0, u)]dMi(u),
where
Dn(t) = n1/2[{S˜(1)W(1)(β0, t) − S
(1)
W(1)
(β0, t)} − eW(1)(β0, t){S˜(0)W(1)(β0, t) − S
(0)
W(1)
(β0, t)}].
The equivalence between (3.23) and (3.24) can be shown by rewriting n1/2[EW(1)(β0, u) −
eW(1)(β0, u)}]S
(0)
W(1)
(β0, u) in the second term of (3.23) as follows:
n1/2[E˜W(1)(β0, t) −EW(1)(β0, t)]S(0)W(1)(β0, t)
=n1/2[
S˜
(1)
W(1)
(β0, t)
S˜
(0)
W(1)
(β0, t)
−
S
(1)
W(1)
(β0, t)
S
(0)
W(1)
(β0, t)
]S(0)
W(1)
(β0, t)
=n1/2[{
S˜
(1)
W(1)
(β0, t)
S˜
(0)
W(1)
(β0, t)
−
S
(1)
W(1)
(β0, t)
S˜
(0)
W(1)
(β0, t)
}
+ {
S
(1)
W(1)
(β0, t)
S˜
(0)
W(1)
(β0, t)
−
S
(1)
W(1)
(β0, t)
S
(0)
W(1)
(β0, t)
}]S(0)
W(1)
(β0, t)
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=n1/2[ 1
S˜
(0)
W(1)
(β0, t)
{S˜(1)W(1)(β0, t) − S
(1)
W(1)
(β0, t)}
+
S
(1)
W(1)
(β0, t)
S˜
(0)
W(1)
(β0, t)S(0)W(1)(β0, t)
{S(0)
W(1)
(β0, t) − S˜(0)W(1)(β0, t)}]S
(0)
W(1)
(β0, t)
=n1/2[{S˜(1)
W(1)
(β0, t) − S(1)W(1)(β0, t)} −EW(1)(β0, t){S˜
(0)
W(1)
(β0, t) − S(0)W(1)(β0, t)}]
× S(0)
W(1)
(β0, t)/S˜(0)W(1)(β0, t)
=Dn(t) +Dn(t){S(0)W(1)(β0, t)/S˜
(0)
W(1)
(β0, t) − 1}
− n1/2{EW(1)(β0, u) − eW(1)(β0, u)}{S˜(0)W(1)(β0, u) − S
(0)
W(1)
(β0, u)}S(0)W(1)(β0, u)/S˜
(0)
W(1)
(β0, u).
Integrand of the fourth term in (3.24) can be shown to converge to in probability to zero,
uniformly in t as its integrand converges to zero uniformly in t, in view of the stability
conditions D and G(iv), combined with the Slutsky’s theorem. The fifth term in (3.24) is a
local square integrable martingale with variance process
∫
1
0
[E˜W(1)(β0, u) −EW(1)(β0, u)]
⊗2
S
(0)
W(2)
(β0, u)λ0(u)du
which converges in probability to zero by conditions C, D, and G(iv). Therefore, if we can
show that the first term in (3.24) and Dn(u) converge jointly in distribution to independent
Gaussian random variables then it implies that Dn(u) converges in distribution to a Gaus-
sian. This further implies that the third term in (3.24) converges in probability to zero and
that the first two terms in (3.24) converge jointly in distribution to independent Gaussian
random variables, which is the desired property. We start showing the joint in distribution
convergence of the first term in (3.24) and Dn(u) through the following Proposition taken
from Self and Prentice [1988].
Proposition 3.4.1. (Self and Prentice [1988]) Let Xn = (X1n, ...,Xnn) and δn = (δ1n, ..., δnn)
be independent random variables such that:
(I) δn is a vector of n˜ ones and n− n˜ zeros, each possible configuration of zeros and ones is
equally likely and n˜/n→p α ∈ (0,1).
(II) For some scalar functions of Xn, fin(Xn), and for any ǫ > 0,
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n−1
n
∑
i=1
[fin(Xn) − f⋅n(Xn)]2I{∣fin(Xn) − f⋅n(Xn)∣ > n1/2ǫ}→p 0,
and S2fn →p σ
2
f > 0, where f⋅n(Xn) = n−1∑ni=1 fin(Xn) and
S2fn = n
−1
n
∑
i=1
[fin(Xn) − f⋅n(Xn)]2.
(III) The scalar functions of Xn, gn(Xn), converge in distribution to a Gaussian random
variable with mean zero and variance σ2g .
Let hn(Xn,δn) = n1/2[n˜−1∑ni=1 δinfin(Xn) − f⋅n(Xn)], then {gn(Xn), hn(Xn,δn)} con-
verge in distribution to a bivariate Gaussian random variable with mean zero and covariance
matrix given by
⎡⎢⎢⎢⎢⎢⎣
σ2g 0
0 (1 − α)α−1σ2f
⎤⎥⎥⎥⎥⎥⎦
.
We can show asymptotic normality of the MSCM case-cohort score statistics via Propo-
sition 3.4.1 as shown below.
Theorem 3.4.2. (Asymptotic normality of the case-cohort MSCM score statistic) Under
conditions A-G,
n−1/2U˜(β0,1) →d N(0,ΣU˜ )
where ΣU˜ = ΣU +∆α,
∆α = ∫
1
0
∫
1
0
G(β0, x, v)λ0(x)λ0(v)dxdv, (3.25)
and G(β0, x, v) is given in the proof below.
Proof. We briefly describe some necessary steps to prove Theorem 3.4.2. Details of the proof
and the calculation of the limiting covariance function are provided in the supplemental
material (§ 3.6).
Our goal can be achieved by showing the first and the second term in (3.24) converge
jointly to independent Gaussian random variables, so that we can claim that the limiting
covariance function of the case-cohort MSCM score process is given by the sum of each
of the limiting covariances. We already have in distribution convergence of the first term,
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which is the full cohort MSCM score function from Theorem 4, but not that of the second
term in (3.24). To show in distribution convergence of the second term to a Gaussian, we
first show in distribution convergence of Dn(⋅).
Consider application of Proposition 1 to Dn(t). In particular, Xin represents {Wi(u),
Yi(u),Ni(u),Ai(u);u ∈ [0,1]}, fin(Xn) represents a linear combination of elements of
Wi(t)Yi(t)r{β′0Ai(t)} and Wi(t)Yi(t)r(1){β′0Ai(t)}. Specifically, fin(Xn) equals to
p
∑
j=1
dj[Wi(tj)Yi(tj)r(1)j {β′0Ai(tj)} − eW(1),j(β0, tj)Wi(tj)Yi(tj)r{β′0Ai(tj)}],
for any constants dj , where j = 1, ..., p. Note that time index can vary by component index
j = 1, ..., p. Condition (I) in Proposition 1 is satisfied by condition G(i) and the fact that
the subcohort is selected by the simple random sampling without replacement. The first
subcondition of condition (II) of Proposition 1 follows from the inequality used by Andersen
and Gill [1982] and Self and Prentice [1988],
∣a − b∣2I{∣a − b∣ > ǫ} ≤ 4∣a∣2I{∣a∣ > ǫ/2} + 4∣b∣2I{∣b∣ > ǫ/2}, (3.26)
by letting n−1/2fin(Xn) be a and n−1/2f⋅n(Xn) be b, combined with conditions D and
G(ii). The second subcondition also follows from bounded property of limiting quantities
implied by D, and stability and regularity property of subcohort covariance function implied
by G(iii). Finally, gn(Xn) represents linear combinations of elements of the full cohort
MSCM score process all evaluated at a finite number of fixed time points in [0,1]. It can
easily be seen that, for any such gn(Xn), condition (III) is satisfied due to the convergence
of the full cohort MSCM score process to a Gaussian process with mean zero and finite
covariance function. It follows that {gn(Xn), hn(Xn, δn)} converges jointly in distribution
to independent Gaussian processes equipped with aforementioned fin(Xn) and gn(Xn).
Then we have joint convergence of the finite dimensional distributions of the MSCM full
cohort score process and a linear combination of elements ofDn(⋅) to Gaussian distributions.
It follows that Dn(⋅) converges in distribution to a multidimensional mean zero Gaussian
random variable by the Cramer-Wold device. As in Self and Prentice [1988], the fact that
linear functionals of the Gaussian processes are Gaussian, combined with the fact that λ0(⋅)
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is absolutely continuous with respect to the Lebesque measure, leads to the conclusion that
the second term in (3.24) converges to a Gaussian random variable. Note that the tightness
condition G(ii) implies weak convergence of the process Dn(⋅) Self and Prentice [1988].
The limiting covariance function of Dn(⋅), say G(β0, x, v), can be shown by straightforward
algebra to equal
G(β0, x, v) = (1 −α)α−1[h(1)(β0, x, v) − eW(1)(β0, x)h(2)(β0, x, v)′ (3.27)
− h(2)(β0, v, x)eW(1)(β0, v)′ + eW(1)(β0, x)eW(1)(β0, v)′h(0)(β0, x, v)]
under conditions D, F, G(i), G(iii), and G(iv), where h(j)(β,x, v) are given by
h(0)(β,x, v) = q(0)(β,x, v) − s(0)
W(1)
(β,x)s(0)
W(1)
(β, v)
h(1)(β,x, v) = q(1)(β,x, v) − s(1)
W(1)
(β,x)s(1)
W(1)
(β, v)′
h(2)(β,x, v) = q(2)(β,x, v) − s(0)
W(1)
(β,x)s(1)
W(1)
(β, v).
Then it can be seen that the covariance function of the limiting process for the second term
in (3.24) conditional on F(1) is given by (3.25) Finally, it follows that the sum of first
two terms in expression (3.24) converge in distribution to a Gaussian random variable with
mean zero and covariance given by Σ
U˜
≡ ΣU +∆α due to independence.
Note S
(j)
W(k)
in condition D equals S(j) for all j = 0,1,2 and k = 1,2 when the IPWs are
equal to 1 (i.e., no weights are considered). Specifically, ΣW(k) equals Σ and (3.25) equals
∆ in Self and Prentice [1988], and hence, ΣU˜ ≡ Σ +∆ in the absence of IPWs.
Theorem 3.4.3. (Asymptotic normality of β˜) Under conditions A-G,
n1/2(β˜ − β0)→d N(0,Σ−1W(1)ΣU˜Σ−1W(1))
where Σ
U˜
is given in the Theorem 3.4.2.
Proof. A Taylor expansion of the MSCM case-cohort score process around β0 evaluated at
β˜ and t = 1 gives
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n−1/2U˜(β0,1) = { − n−1∂
2 l˜(β˙,1)
∂β2
}n1/2(β˜ − β0) (3.28)
for any β˙ on the line segment between β˜ and β0. It is clear that we need to show (in
probability) convergence of −n−1∂2 l˜(β˙,1)/∂β2, for any β˙ in between β˜ and β0. First, let
n−1I˜(β, t) = −n−1∂2 l˜(β, t)/∂β2, and (3.29)
n−1I(β, t) = −n−1∂2l(β, t)/∂β2. (3.30)
Here, we consider asymptotic properties of (3.30) instead of (3.29) because the two pro-
cesses converge in probability to the same quantity. To see this, note
sup
β,t
∣n−1{I(β, t) − I˜(β, t)}∣ (3.31)
≤n−1
n
∑
i=1
∫
1
0
sup
β,u
∣Wi(u){V˜W(1)(β,u) − VW(1)(β,u)}∣dNi(u)
≤M1∫
1
0
sup
β,u
∣{V˜W(1)(β,u) − VW(1)(β,u)}∣n−1
n
∑
i=1
dNi(u) →p 0
for any (β, t) ∈ B × [0,1] due to conditions B, D, F, G(iv), by the continuous mapping
theorem, and the fact that the total number of jumps are bounded by n. Here, V˜W(1) =
S˜
(2)
W(1)
/S˜(0)W(1) − (S˜
(1)
W(1)
/S˜(0)W(1))
⊗2. Therefore, it is sufficient to show that n−1I(β,1) converges
in probability to a fixed matrix. Using (3.10), decompose n−1I(β0,1) by
n−1
n
∑
i=1
∫
1
0
Wi(u)[
S
(2)
W(1)
(β0, u)S(0)W(1)(β0, u) − {S
(1)
W(1)
(β0, u)}⊗2
S
(0)
W(1)
(β0, u)2
]dMi(u)
+ ∫
1
0
[
S
(2)
W(1)
(β0, u)S(0)W(1)(β0, u) − {S
(1)
W(1)
(β0, u)}⊗2
S
(0)
W(1)
(β0, u)2
]S(0)
W(1)
(β0, u)λ0(u)du.
The elements of the first term are local square integrable martingale with variance process
for the (i, j) element equals
n−1∫
1
0
{VW(1)(β,u)}
2
ij
S
(0)
W(2)
(β0, u)λ0(u)du
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which converges in probability to zero by virtue of the stability, regularity, and boundedness
conditions A-F. It follows that
n−1I(β,1) →p∫
1
0
vW(1)(β0, u)s
(0)
W(1)
(β0, u)λ0(u)du = ΣW(1) (3.32)
for any β ∈ B, and therefore n−1I(β˙,1) →p ΣW(1) for any β˙ in between β˜ and β0. Then
Theorem 3.4.2 along with (3.28) complete the proof. In particular, the covariance matrix
Σ−1W(1)ΣU˜Σ
−1
W(1)
has a form
Σ−1W(1)(ΣU +∆α)Σ−1W(1) = Σ−1W(1)(ΣW(2) +∆W(1),W(2) +∆α)Σ−1W(1)
where ΣU = ΣW(2) +∆W(1),W(2) as in Theorem 3.4.1 and the explicit form of ∆α is given by
(3.25).
Note (3.32) converges to Σ when Wi(t) = 1 for all i and t. Then n1/2(β˜ − β0) converges
to mean zero Gaussian vector with the same variance matrix as in Self and Prentice [1988].
Based on Theorem 3.4.3, we propose a new variance estimator
v̂ar(β˜) = n−1Σˆ−1W(1)(ΣˆW(2) + ∆ˆW(1),W(2) + ∆ˆα)Σˆ−1W(1) , (3.33)
where
ΣˆW(1) = n
−1I˜(β˜,1;W = Wˆ ), (3.34)
ΣˆW(2) = n
−1I˜(β˜,1;Wˆ 2), (3.35)
∆ˆW(1),W(2) = n
−1
n
∑
i=1
∫
1
0
Wˆi(u)2[E˜{W(2)=Wˆ 2}(β˜, u) (3.36)
− E˜{W(1)=Wˆ}(β˜, u)]
⊗2
dNi(u), and
∆ˆα = n
−2∫
1
0
∫
1
0
Gˆ(β˜, x, v)S˜(0)
W (1)
(β˜, x)−1 (3.37)
× S˜(0)
W (1)
(β˜, v)−1dN
Wˆ
(x)dN
Wˆ
(v),
where Wˆ or Wˆ 2 means that the IPWs are replaced by Wˆ or squared values of Wˆ , E˜{W(2)=Wˆ 2}
and E˜{W(1)=Wˆ}
denote that the IPWs in E˜W(2) and E˜W(1) are replaced by Wˆ , N Wˆ (t) is
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defined by ∑i Wˆi(t)Ni(t), and Gˆ(β˜, ⋅, ⋅) is (3.27) with h(j)(β0, ⋅), eW(1)(β0, ⋅), and s(0)W(1)(β0, ⋅)
replaced by H˜(j)(β˜, ⋅), E˜W(1)(β˜, ⋅), and S˜(0)W(1)(β˜, ⋅). Estimators (3.34), (3.35), and (3.36) are
consistent estimators of ΣW(1) , ΣW(2) , and ∆W(1),W(2) in view of (3.31) and (3.32) along
with condition A. Estimator (3.37) is a consistent estimator of ∆α in view of conditions A,
G(ii), that n−1N
Wˆ
(t) uniformly converges to ∫ t0 s(0)W(1)(β0, u)λ0(u)du, and that n−1N Wˆ (1)
is bounded in probability.
The proposed variance estimator (3.33) is different from the robust estimator proposed
by Lin and Ying (LY,Lin and Ying [1993]) that is used in most MSM analyses. Both (3.33)
and the LY estimator are sandwich-type estimators where the “bread” of sandwich (Σˆ−1W(1))
is the same. The difference comes from the “meat”. The proposed variance estimator
requires calculation of ∆ˆα which reflects covariance among score components induced by
the subcohort sampling. The covariance matrix of the MSCM case-cohort score statistic
ΣU˜ +∆α is estimated without explicit estimation of ∆α if the LY estimator is used. It can
be seen that calculation of the LY estimator is based on (weighted) score residuals. When
sample size is small, the score residuals will be correlated due to the substitution of β˜ or β∗
for β, which might lead to underestimation of the true variance. Simulation results reported
in §3.5.2 below indicate that (3.33) may be more accurate when the size of subcohort is
small.
3.5 Implementation and Simulation
We have shown that we can obtain a consistent and asymptotically normally distributed
estimator of treatment effect in the case-cohort setting by fitting a MSCM via inverse
probability weighting. This provides theoretical justification for simulation results shown in
Cole et al. [2012]. In this section we (i) describe how a MSCM can easily be fit via inverse
probability weighting for either the full cohort or case-cohort setting using standard survival
analysis software, such as R or SAS, and (ii) present results from a simulation study.
3.5.1 Implementation
To fit a MSCM via inverse probability weighting for a full cohort, first create a data set in
which each person-visit corresponds to one row. Specifically, let each row contain a subject
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identifier, visit (or date) information, treatment and time-varying confounder information
at the corresponding visit/date time, and baseline covariates. Depending upon the user-
defined models to estimate Wi(t), the data set may be augmented by treatment/covariate
histories in each row as well. For example, one might fit pooled logistic models to obtain
the estimated probability of receiving treatment at time t by regressing the log-odds of
receiving treatment A(t) on prior treatment status (say, A(t−)) alone (for the numerator
in (4.2)), or with current covariate information L(t) (for the denominator in (4.2)) Herna´n,
Brumback and Robins [2001]. Analogously, the estimated probability of being uncensored
at time t can be obtained by regressing the log-odds of being uncensored (C(t) = 0) on
current treatment status (A(t)) alone, or with L(t). For such models flexible functional
forms (e.g., splines) are often used for continuous confounders Cole and Herna´n [2008]; Cole
et al. [2012, 2003]. Predicted values of the denominator and numerator probabilities in (4.2)
and (3.6) can then be used to calculate Wˆi(t) for all participants i = 1, ..., n and all study
visit times t. Then Wˆi(t) needs to be added to the data set to fit the MSCM. Finally, the
data set should be prepared in the counting process type format whereby each row contains
the start and stop times corresponding to the previous and current visits, along with an
event status indicator for the current visit. Then standard software can be used to fit the
MSCM via inverse probability weighting. For instance, using the survival package in R
[Therneau, 2012], the following code can be used:
coxph(Surv(start, stop, delta) ~ trt, weight=w)
where delta is the event indicator having value 1 if an event occurred at stop and 0
otherwise, trt indicates whether an individual received treatment (assuming treatment is
a scalar) over the interval (start, stop], and w is Wˆi(t). The same model can be fit in
SAS by using the following code:
proc phreg data = dataname covout;
model (start,stop)*delta(0)=trt;
weight w;
run;
Fitting a MSCM in the case-cohort setting can be accomplished with some additional
data modifications. First, prepare a reduced data set including the randomly selected n˜
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subcohort members and all cases. Second, estimate the individual-time-specific weights
Wi(t) based on the user-specified model as before (e.g., logistic regression), except with
individuals in the subcohort that are not cases weighted by n/n˜ [Cole et al., 2012]. After
adding the estimated individual-time-specific weights Wˆi(t) to each person-visit row, modify
each nonsubcohort case to contribute only one line of data with start time tj − ǫ and stop
time tj where tj is the event time for that individual and ǫ is chosen to be very small,
for instance ǫ = 0.0001. This insures that nonsubcohort cases appear only in the risk set
when they fail. One should make sure that the start times for nonsubcohort cases are
positive, such that tj − ǫ > 0 for your choice of ǫ. This modification of the data set for the
nonsubcohort cases is sufficient to obtain β∗, and the same R/SAS code as above can be
employed using the modified data set. Obtaining β˜ can be accomplished with an additional
data step wherein a dummy variable is coded equal to a relatively small negative value
(e.g., -20) for nonsubcohort cases and 0 otherwise [Therneau and Li, 1999]. Then, β˜ can be
obtained as follows in R:
coxph(Surv(start, stop, delta) ~ trt + offset(dummy), weight=w)
or in SAS:
proc phreg data = dataname covout;
model (start,stop)*delta(0)=trt/offset=dummy;
weight w;
run;
The offset term enforces a relative weight of exp(−20) < 10−8, assuming -20 is used for the
dummy value, to the nonsubcohort cases so that they effectively do not contribute to the
sum of the log (inside the integral) in (3.8). Therneau and Li [1999] suggested using -100
(exp(−100) < 10−40) for the dummy variable value, however, we found that sometimes the
coxph function in R did not converge when dummy = −100; this convergence problem was
observed when the event rate was very low, say 3-4%. Therefore, we recommend several
dummy values be considered to ensure robustness of analysis results. The choice of dummy
= −20 yielded reasonable analysis results under average event rate ≥5% in our simulation
study.
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The proposed variance estimator (3.33) requires computation of four components: Σˆ−1W(1) ,
ΣˆW(2) , ∆ˆW(1),W(2), and ∆ˆα. The naive variance estimator obtained by fitting the Cox model
with the weight option is the inverse of minus the second derivative of l˜(β,1) evaluated
at β˜ (i.e., I˜−1(β˜,1), the inverse of the observed information matrix) which is n−1 times
Σˆ−1W(1) . Therefore, Σˆ
−1
W(1)
can be obtained by multiplying n times the naive variance estimate.
Likewise, ΣˆW(2) can be obtained by multiplying n
−1 times the inverse of the naive variance
estimate obtained by fitting the Cox model with the variable weight equal to the square of
the original weight variable. Unfortunately, it does not seem that ∆ˆW(1),W(2) and ∆ˆα can be
obtained as simply as ΣˆW(1) or ΣˆW(2). One can create vectors/matrices of S˜
(j)
Wˆk
(β˜, ⋅), and then
calculate E˜
Wˆk
(β˜, ⋅), Q˜(j)(β˜, ⋅), and H˜(j)(β˜, ⋅) to obtain ∆ˆW(1),W(2) and ∆ˆα. Alternatively,
one may want to apply the LY estimator in practice [Cole et al., 2012]. The LY estimator
appears to perform well empirically if we have moderate subcohort size and event rate (Cole
et al. [2012], §3.5.2 below), and is computationally straightforward to implement. The LY
estimator associated with β˜ can be obtained by using the following R or SAS code:
coxph(Surv(start, stop, delta) ~ trt + offset(dummy)
+ cluster(id), weight=w)
proc phreg data = dataname covs(aggregate) covout;
id id;
model (start,stop)*delta(0)=trt/offset=dummy;
weight w;
run;
The LY estimator corresponding to β∗ can be obtained by deleting offset(dummy) or
/offset=dummy.
3.5.2 Simulation
A simulation study was conducted to examine the finite sample bias of β˜ and β∗, and
performance of the proposed variance estimator (3.33) as well as the LY variance estimator.
Simulations were conducted similar to Cole et al. [2012]. Briefly, potential survival times
were generated according to the MSCM (3.4), and observed survival times were generated
by stochastically generating time varying exposures and confounders for cohorts of size
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Table 3.1: Summary of simulation study
Sub- Event Esti- Bias ESE ASE Coverage
cohort(%) rate(%) mator proposed LY proposed LY
5 5 † β∗ -0.12 0.49 0.55 0.42 0.97 0.91
β˜ -0.20 0.68 0.66 0.47 0.96 0.90
25 β∗ -0.03 0.37 0.36 0.31 0.94 0.91
β˜ -0.04 0.44 0.37 0.35 0.92 0.91
10 5 β∗ -0.05 0.40 0.42 0.37 0.97 0.94
β˜ -0.06 0.44 0.43 0.39 0.96 0.94
25 β∗ -0.02 0.27 0.26 0.26 0.93 0.93
β˜ -0.02 0.29 0.26 0.26 0.93 0.93
20 5 β∗ -0.02 0.35 0.36 0.34 0.96 0.95
β˜ -0.02 0.36 0.36 0.35 0.96 0.95
25 β∗ -0.01 0.21 0.20 0.20 0.94 0.94
β˜ -0.01 0.21 0.20 0.20 0.94 0.94
Bias denotes the empirical bias of the different estimators of β0. ASE denotes the average
estimated standard errors. ESE denotes the empirical standard errors. Coverage denotes
the empirical coverage of 95% Wald-type confidence intervals using either (3.33) or the LY
variance estimator. † Of the 5000 estimates of β∗ and β˜, one was excluded because some
of the unstabilized IPWs were greater than 106.
n = 1,000 (see Cole et al. [2012] for details). While Cole et al. [2012] considered only one
scenario having a 25% event rate (i.e., 25% of individuals were cases) and a 20% subcohort
fraction (i.e., n˜n−1×100), we considered 36 scenarios by varying both the subcohort fraction
and the event rate from 5 to 30% (in increments of 5%). Censoring times were generated
from uniform distributions with support chosen to achieve the desired event rate. We did
not incorporate IPCWs when calculating IPWs because the censoring times were generated
independent of the exposure and potential survival times. Following Cole et al. [2012],
unstabilized weights were used to calculate IPWs. For each scenario 5,000 data sets were
generated under the null β0 = 0 and the alternative β0 = log(1/2).
Results from the simulation study are summarized in Table 1. Only results obtained
from six scenarios under the null are presented; results from other scenarios and under the
alternative were similar. For all scenarios, under both the null and alternative, β˜ and β∗
were nearly unbiased; that the two estimators performed similarly is not surprising in light of
Theorem 3. Under the null, the proposed variance estimator was always less biased than the
LY variance estimator when the subcohort fraction was only 5%, regardless of the event rate.
Similarly, (3.33) was less biased regardless of the subcohort fraction when the event rate
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was 5%. Both the proposed and the LY variance estimators were approximately unbiased
when the subcohort fraction and event rate were both greater than 15%. Wald confidence
intervals (CIs) using the LY variance estimator tended to undercover when the subcohort
fraction was 5%, whereas Wald CIs using (3.33) exhibited coverage close to the nominal level
for all scenarios considered. In summary, both β˜ and β∗, along with the proposed variance
estimator and CIs, exhibited good finite sample properties for the scenarios considered,
while performance of the LY variance estimator depended on subcohort size and event
rate.
3.6 Supplemental Material
This supplementary material contains three parts: § 3.6 provides detailed steps to apply
Proposition 1 to show asymptotic normality of the MSCM case-cohort score process (Theo-
rem 3.4.2). § 3.6 justifies the application of Proposition 1 by showing that fin(Xn) satisfies
conditions in Proposition 1. § 3.6 shows detailed calculations to obtain limiting covariance
function of the MSCM case-cohort score process.
Application of Proposition 1
Our goal is to show that the difference of the first two terms in (3.24), which is given by
n−1/2
n
∑
i=1
∫
t
0
Wi(u)[Ai(u) −EW(1)(β0, u)]dMi(u) − ∫
t
0
Dn(u)λ0(u)du
=Bn(t) − ∫
t
0
Dn(u)λ0(u)du
=Bn(t) −Cn(t)
converges in distribution to a finite dimensional Gaussian random variable where Bn(⋅),
Cn(⋅), and Dn(⋅) are defined by
Bn(t) = n−1/2
n
∑
i=1
∫
t
0
Wi(u)[Ai(u) −EW(1)(β0, u)]dMi(u), (3.38)
Cn(t) = ∫
t
0
Dn(u)λ0(u)du, and (3.39)
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Dn(u) = n1/2[{S˜(1)W(1)(β0, u) − S
(1)
W(1)
(β0, u)} − eW(1)(β0, u) (3.40)
× {S˜(0)
W(1)
(β0, u) − S(0)W(1)(β0, u)}]S
(0)
W(1)
(β0, u).
Let gn(Xn) be a linear combination of elements of the MSCM full cohort score process
(Bn), i.e., for any constants cj (j = 1, .., p),
gn(Xn) = n−1/2
n
∑
i=1
p
∑
j=1
cj ∫
t
0
Wi(u)[Ai,j(u) −EW(1),j(β0, u)]dMi(u)
where the subscript j denotes the jth component of a vector. Also, let hn(Xn, δn) be a
linear combination of elements of Dn, i.e., for any constants dj(j = 1, .., p), fin(Xn) is given
by
fin(Xn) =
p
∑
j=1
dj[Wi(uj)Yi(uj)r(1)j {β′0Ai(uj)} (3.41)
− eW (1),j(β0, uj)Wi(uj)Yi(uj)r{β′0Ai(uj)}].
Then (3.41) leads to the desired form of hn(Xn, δn):
hn(Xn, δn) =n1/2[n˜−1
n
∑
i=1
δinfin(Xn) − f⋅n(Xn)]
=n1/2[
p
∑
j=1
dj{S˜(1)W(1),j(β0, uj) − eW(1),j(β0, uj)S˜
(0)
W(1)
(β0, uj)}
−
p
∑
j=1
dj{S(1)W(1),j(β0, uj) − eW(1),j(β0, uj)S
(0)
W(1)
(β0, uj)}]
=n1/2
p
∑
j=1
dj[{S˜(1)W(1),j(β0, uj) − S
(1)
W(1),j
(β0, uj)}
− eW(1),j(β0, uj){S˜(0)W(1)(β0, uj) − S
(0)
W(1)
(β0, uj)}]
which is a linear combination of elements of Dn where each jth component can be evaluated
at possibly different time points uj, i.e.,
hn(Xn, δn) =
p
∑
j=1
djDn,j(uj)
Assume that fin(Xn) and gn(Xn) satisfy conditions stated in Proposition 1, which will
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be shown in the Part II later in the supplementary material. Then by varying cj and dj ,
we can show that any chosen elements of Bn and Dn jointly converge in distribution to
an independent bivariate Gaussian process by application of Proposition 1. For example,
consider c1 = d1 = 1 and c2 = ... = cp = d2 = ... = dp = 0. Then Proposition 1 states that
the first element of Bn and the first element of Dn converge jointly in distribution to an
independent bivariate Gaussian. In iterative fashion, we can show that jth element of
Bn and kth element of Dn converge in distribution to an independent bivariate Gaussian
for all combinations of (j, k) ∈ [1,2, ..., p] × [1,2, ..., p]. Therefore, Bn and Dn converge in
distribution to independent processes. We have shown that Bn, the MSCM full cohort score
process, converges in distribution to a Gaussian process. Therefore, what we have left to
show is that Dn converges in distribution to a Gaussian process (and later to show that Cn
converges in distribution to a Gaussian process).
In the above arguments we have shown that, for any dj (j = 1, ..., p), ∑pj=1 djDn,j con-
verges in distribution to a univariate Gaussian because fin(Xn) satisfies conditions in Propo-
sition 1 for any dj (which, as we mentioned above, will be shown in the Part II). Therefore,
it follows that Dn converges in distribution to a multidimensional mean zero Gaussian ran-
dom variable by the Cramer-Wold device. As in Self and Prentice [1988], the fact that
linear functionals of the Gaussian processes are Gaussian combined with the fact that λ0(⋅)
is absolutely continuous with respect to the Lebesque measure leads to that Cn converges
to a Gaussian random variable, say C. Then it follows that Bn − Cn converges to a mean
zero Gaussian random variable with covariance ΣU +∆α, as the limiting covariance of Cn
will be shown to equal ∆α later in the Part II.
In the next two parts, we verify that fin(Xn) and gn(Xn) satisfy conditions in Propo-
sition 1, and show the explicit form of limiting covariance structure of Cn respectively.
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Condition (II) in Proposition 1
Recall that condition (II) of Proposition 1 has the following two subconditions:
For any ǫ > 0,
n−1
n
∑
i=1
[fin(Xn) − f⋅n(Xn)]2I{∣fin(Xn)−f⋅n(Xn)∣>n1/2ǫ} →p 0, and (3.42)
S2fn = n
−1
n
∑
i=1
[fin(Xn) − f⋅n(Xn)]2 →p σf . (3.43)
To show (3.42) based on the inequality (3.26), we need to show that for any ǫ > 0,
n−1
n
∑
i=1
∣fin(Xn)∣2I{∣fin(Xn)∣ > n1/2ǫ/2}→p 0, and (3.44)
n−1∣f⋅n(Xn)∣2I{∣f⋅n(Xn)∣ > n1/2ǫ/2}→p 0. (3.45)
To show (3.44), recall condition G(ii): For any ǫ > 0
sup
t
n−1
n
∑
i=1
Wi(t)2Yi(t)r{β′0Ai(t)}2 (3.46)
× I{n−1/2Wi(t)Yi(t)r{β′0Ai(t)} > ǫ}→p 0,
sup
t
n−1
n
∑
i=1
Wi(t)2Yi(t)∣∣r(1){β′0Ai(t)}∣∣2 (3.47)
× I{n−1/2Wi(t)Yi(t)∣∣r(1){β′0Ai(t)}∣∣ > ǫ}→p 0,
where (3.46) implies
sup
t
n−1
n
∑
i=1
Wi(t)2Yi(t)r{β′0Ai(t)}2∣∣eW(1)(β0, t)∣∣2 (3.48)
× I{n−1/2Wi(t)Yi(t)r{β′0Ai(t)}∣∣eW(1)(β0, t)∣∣ > ǫ}→p 0.
It can be shown that (3.47) and (3.48) imply (3.44), by repeatedly applying (3.26).
Also, we can rewrite
f⋅n(Xn) =
p
∑
j=1
dj[S(1)W(1),j(β0, t) − eW(1),j(β0, t)S
(0)
W(1)
(β0, t)].
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Then (3.45) can immediately be seen by the stability property implied by condition D.
To show (3.43), note that S2fn can be rewritten as
S2fn = n
−1
n
∑
i=1
[fin(Xn) − f⋅n(Xn)]2 (3.49)
= n−1
n
∑
i=1
fin(Xn)2 − {f⋅n(Xn)}2.
For notational and calculational convenience, let
fin(Xn) =
p
∑
j=1
dj(aj − bj)
by letting
aj =Wi(uj)Yi(uj)r(1)j {β′0Ai(uj)}, and
bj = eW (1),j(β0, uj)Wi(uj)Yi(uj)r{β′0Ai(uj)}
then calculate the form of each term in (3.49). First term in (3.49) can be written as follows:
n−1
n
∑
i=1
fin(Xn)2 = n−1
n
∑
i=1
[
p
∑
j=1
dj(aj − bj)]
2
=n−1
n
∑
i=1
[
p
∑
j=1
d2j(aj − bj)2 + 2∑
j<k
djdk(aj − bj)(ak − bk)]
=n−1
n
∑
i=1
[
p
∑
j=1
d2j{Wi(uj)2Yi(uj)r(1)j {β′0Ai(uj)}2
− 2Wi(uj)Yi(uj)r(1)j {β′0Ai(uj)}eW (1),j(β0, uj)Wi(uj)Yi(uj)r{β′0Ai(uj)}
+ eW (1),j(β0, uj)2Wi(uj)2Yi(uj)r{β′0Ai(uj)}2}
+ 2∑
j<k
djdk{Wi(uj)Yi(uj)r(1)j {β′0Ai(uj)}Wi(uk)Yi(uk)r
(1)
k
{β′0Ai(uk)}
−Wi(uj)Yi(uj)r(1)j {β′0Ai(uj)}eW (1),k(β0, uk)Wi(uk)Yi(uk)r{β′0Ai(uk)}
− eW (1),j(β0, uj)Wi(uj)Yi(uj)r{β′0Ai(uj)}Wi(uk)Yi(uk)r(1)k {β′0Ai(uk)}
+ eW (1),j(β0, uj)Wi(uj)Yi(uj)r{β′0Ai(uj)}eW (1),k(β0, uk)Wi(uk)Yi(uk)
× r{β′0Ai(uk)}}]
Then using Q(j)(j = 0,1,2) notation defined in condition G(iii), the above equation can be
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abbreviated as
n−1
n
∑
i=1
fin(Xn)2 =
p
∑
j=1
d2j{Q(1)(j,j)(β0, uj , uj) − 2eW (1),j(β0, uj)Q(2)j (β0, uj , uj)
+ eW (1),j(β0, uj)2Q(0)(β0, uj , uj)}
+2∑
j<k
djdk{Q(1)(j,k)(β0, uj , uk) − eW (1),k(β0, uk)Q(2)j (β0, uk, uj)
− eW (1),j(β0, uj)Q(2)k (β0, uj , uk)
+ eW (1),j(β0, uj)eW (1),k(β0, uk)Q(0)(β0, uj , uk)}.
Now it can be seen that the above equation converges in probability to a fixed quantity in
view of stability properties of Q(⋅) stated in condition G(iii). The convergence of f⋅n(Xn)
can be shown using the same manner as the above. In particular, let
f⋅n(Xn) =
p
∑
j=1
dj(aj − bj)
where
aj = S
(1)
W(1),j
(β0, uj), and
bj = eW (1),j(β0, uj)S(0)W(1)(β0, uj),
then
{f⋅n(Xn)}2 =
p
∑
j=1
d2j{S(1)W(1),j(β0, uj)
2 − 2S(1)W(1),j(β0, uj)eW (1),j(β0, uj)S
(0)
W(1)
(β0, uj)
+ eW (1),j(β0, uj)2S(0)W(1)(β0, uj)2}
+ 2∑
j<k
djdk{S(1)W(1),j(β0, uk)S
(1)
W(1),k
(β0, uk)
− S(1)
W(1),j
(β0, uj)eW (1),k(β0, uk)S(0)W(1)(β0, uk)
− eW (1),j(β0, uj)S(0)W(1)(β0, uj)S
(0)
W(1)
(β0, uk)
+ eW (1),j(β0, uj)S(0)W(1)(β0, uj)eW (1),k(β0, uk)S
(0)
W(1)
(β0, uk)}
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Then without further calculation, it can be seen that the above equation also converges to
a fixed quantity by conditions D and G(iii), and therefore we prove that (3.43) holds.
Limiting Covariance function
Now we need to show the limiting covariance function of Cn. First we will show the
limiting covariance function of Dn.
Let hn(Xn, δn) = Dn,j(uj) + Dn,k(uk) (i.e., let dj = dk = 1 and dl = 0 for all l ≠ j in
∑pj=1 djDn,j(uj)). Covariance between Dn,j(uj) and Dn,k(uk) is given by
Cov(Dn,j(uj),Dn,k(uk)) (3.50)
= {Var(hn(Xn, δn)) −Var(Dn,j(uj)) −Var(Dn,k(uk))}/2.
Then the limiting values of (3.50) will lead to the (j, k)th components of the limiting
covariance, i.e.,
lim
n→∞
Cov(Dn,j(uj),Dn,k(uk)) (3.51)
= lim
n→∞
{Var(hn(Xn, δn)) −Var(Dn,j(uj)) −Var(Dn,k(uk))}/2.
By Proposition 1, we can obtain limiting values of Var(hn(Xn, δn)), Var(Dn,j(uj)) and
Var(Dn,k(uk)) using sample covariances calculated based on corresponding fin(Xn) equipped
with condition G(iii) and G(iv). Note that condition G(iii) ensures the convergence of the
finite sample covariance function to that of the limiting distribution. For notational conve-
nience, let
Fin,j(Xn) = [Wi(uj)Yi(uj)r(1)j {β′0Ai(uj)}
− eW (1),j(β0, uj)Wi(uj)Yi(uj)r{β′0Ai(uj)}], and
F⋅n,j(Xn) = n−1
n
∑
i=1
Fin,j(Xn); j = 1, ..., p.
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Now, straightforward calculation based on Proposition 1 yields that
lim
n→∞
{Var(hn(Xn, δn)) −Var(Dn,j(uj)) −Var(Dn,k(uk))}
=(1 − α)α−1 lim
n→∞
n−1
n
∑
i=1
[Fin,j(Xn) +Fin,k(Xn) − {F⋅n,j(Xn) +F⋅n,k(Xn)}]
2
− (1 −α)α−1 lim
n→∞
n−1
n
∑
i=1
[Fin,j(Xn) −F⋅n,j(Xn)]
2
− (1 −α)α−1 lim
n→∞
n−1
n
∑
i=1
[Fin,k(Xn) −F⋅n,k(Xn)]
2
=(1 − α)α−1{ lim
n→∞
n−1
n
∑
i=1
[Fin,j(Xn) +Fin,k(Xn) − {F⋅n,j(Xn) +F⋅n,k(Xn)}]
2
− lim
n→∞
n−1
n
∑
i=1
[Fin,j(Xn) −F⋅n,j(Xn)]
2
− lim
n→∞
n−1
n
∑
i=1
[Fin,k(Xn) −F⋅n,k(Xn)]
2
}.
The whole term after (1 −α)α−1 can be simplified as follows:
lim
n→∞
n−1
n
∑
i=1
[{Fin,j(Xn)2 + 2Fin,j(Xn)Fin,k(Xn) +Fin,k(Xn)2}
− 2{Fin,j(Xn) +Fin,k(Xn)}{F⋅n,j(Xn) +F⋅n,k(Xn)}
+ {F⋅n,j(Xn)2 + 2F⋅n,j(Xn)F⋅n,k(Xn) +F⋅n,k(Xn)2}]
− lim
n→∞
n−1
n
∑
i=1
[Fin,j(Xn)2 − 2Fin,j(Xn)F⋅n,j(Xn) +F⋅n,j(Xn)2]
− lim
n→∞
n−1
n
∑
i=1
[Fin,k(Xn)2 − 2Fin,k(Xn)F⋅n,k(Xn) +F⋅n,k(Xn)2]
= lim
n→∞
n−1
n
∑
i=1
2[Fin,j(Xn)Fin,k(Xn) −Fin,j(Xn)F⋅n,k(Xn) −Fin,k(Xn)F⋅n,j(Xn)
+F⋅n,j(Xn)F⋅n,k(Xn)]
= lim
n→∞
2[n−1
n
∑
i=1
Fin,j(Xn)Fin,k(Xn) −F⋅n,j(Xn)F⋅n,k(Xn)],
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where the first term inside the bracket is given by
n−1
n
∑
i=1
Fin,j(Xn)Fin,k(Xn)
=n−1
n
∑
i=1
[Wi(uj)Yi(uj)r(1)j {β′0Ai(uj)}Wi(uk)Yi(uk)r
(1)
k
{β′0Ai(uk)}
− eW (1),j(β0, uj)Wi(uj)Yi(uj)r{β′0Ai(uj)}Wi(uk)Yi(uk)r(1)k {β′0Ai(uk)}
−Wi(uj)Yi(uj)r(1)j {β′0Ai(uj)}Wi(uk)Yi(uk)r{β′0Ai(uk)}eW (1),k(β0, uk)
+ eW (1),j(β0, uj)Wi(uj)Yi(uj)r{β′0Ai(uj)}Wi(uk)Yi(uk)r{β′0Ai(uk)}eW (1),k(β0, uk)]
=Q
(1)
(j,k)
(β0, uj , uk) − eW (1),j(β0, uj)Q(2)k (β0, uj , uk)
−Q(2)j (β0, uk, uj)eW (1),k(β0, uk) + eW (1),j(β0, uj)Q(0)(β0, uj , uk)eW (1),k(β0, uk),
and the second term inside the bracket is given by
F⋅n,j(Xn) −F⋅n,k(Xn) =S(1)W(1),j(β0, uj)S
(1)
W(1),k
(β0, uk)
− eW (1),j(β0, uj)S(0)W(1)(β0, uj)S
(1)
W(1),k
(β0, uk)
− S(1)
W(1),j
(β0, uj)eW (1),k(β0, uk)S(0)W(1)(β0, uk)
+ eW (1),j(β0, uj)S(0)W(1)(β0, uj)S
(0)
W(1)
(β0, uk)eW (1),k(β0, uk).
Then limn→∞ 2[n−1∑ni=1Fin,j(Xn)Fin,k(Xn) −F⋅n,j(Xn)F⋅n,k(Xn)] can be rewritten as
lim
n→∞
2[{Q(1)
(j,k)
(β0, uj , uk) − S(1)W(1),j(β0, uj)S
(1)
W(1),k
(β0, uk)}
− eW (1),j(β0, uj){Q(2)k (β0, uj , uk) − S(0)W(1)(β0, uj)S
(1)
W(1),k
(β0, uk)}
− {Q(2)j (β0, uk, uj) − S(0)W(1)(β0, uk)S
(1)
W(1),j
(β0, uj)}eW (1),k(β0, uk)
+ eW (1),j(β0, uj){Q(0)(β0, uj , uk) − S(0)W(1)(β0, uj)S
(0)
W(1)
(β0, uk)}eW (1),k(β0, uk)]
= lim
n→∞
2[H(1)
(j,k)
(β0, uj , uk) − eW (1),j(β0, uj)H(2)k (β0, uj , uk)
−H(2)j (β0, uk, uj)eW (1),k(β0, uk) + eW (1),j(β0, uj)H(0)(β0, uj , uk)eW (1),k(β0, uk)],
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where
H(0)(β,x, v) = Q(0)(β,x, v) − S(0)W(1)(β,x)S
(0)
W(1)
(β, v)
H(1)(β,x, v) = Q(1)(β,x, v) − S(1)
W(1)
(β,x)S(1)
W(1)
(β, v)′
H(2)(β,x, v) = Q(2)(β,x, v) − S(0)
W(1)
(β,x)S(1)
W(1)
(β, v).
It follows that (3.51) is the (j, k)th element of G(β0, uj , uk) in view of convergence property
implied by conditions D and G(iii). Then it can be seen that the limiting covariance function
of Dn is given by G, and therefore we complete showing the in distribution convergence
of (3.40) to a Gaussian random variable. By applying the basic properties of covariance
matrix, we obtain the limiting covariance function of Cn given by ∆α.
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Chapter 4
Efficient Inference of Case-Cohort Marginal Structural Cox Models
4.1 Introduction
Marginal structural models (MSMs) are useful tools to make causal inference from longi-
tudinal observational studies in the presence of time-varying confounders; time-dependent
variables that predict subsequent treatment. MSMs are made upon the notion of po-
tential outcome introduced by Neyman [1923] and Rubin [1974]. The method for ob-
taining MSM estimators accounts for confounding by incorporating inverse-probability-of-
treatment-weights (IPTW) and enables to study causal relationship between exposures and
outcome. In this paper, we focus on evaluating causal effect of treatment on time to disease
occurrence in longitudinal observational studies, in the presence of confounding.
Recently, Cole et al. [2012] considered employing the case-cohort design to the MSCM
analysis as a cost-efficient approach. The case-cohort study involves two-phase sampling:
simple random sampling without replacement to form a full cohort from an infinite su-
perpopulation at phase 1, and random sampling a subcohort from the full cohort as well
as sampling all subjects who experience a predefined event (henceforth, cases) at phase 2.
Subcohort and cases will form case-cohort sample. We refer variables that are observed
from the full cohort to as phase 1 variables, and refer variables only available for the case-
cohort sample to as phase 2 variables. We can achieve cost and effort saving by restricting
collection of expensive variables based upon phase 2 subjects only. For example, high cost
associated with determination of covariate information such as CD4 counts or viral load
from biomarkers in HIV studies, or the cost associated with genotyping a large number of
subjects in genetic studies can be avoid by employing the case-cohort design.
Prentice [1986a] described a pseudo-likelihood approach for the hazard ratio parame-
ter estimation in the Cox model along with heuristic procedures for parameter estimation
when the case-cohort design is applied. Asymptotic distribution theory of the case-cohort
maximum pseudo-likelihood estimator was developed by Self and Prentice [1988] using mar-
tingale technique and finite population convergence results. Both Prentice [1986a] and Self
and Prentice [1988] do not accommodate inverse weights accounting for sampling of sub-
jects, i.e., they considered unweighted pseudo-likelihoods.
After Prentice [1986a] and Self and Prentice [1988], various methods have been pro-
posed as means of improving the efficiency of the hazard ratio estimation (compared to
Prentice [1986a] and Self and Prentice [1988]) in the standard (associational) case-cohort
Cox regression analysis. Barlow [1994] and Barlow et al. [1999] considered estimators based
on weighted pseudo-likelihood estimation. At each failure time, contribution of cases and
nonfailures (controls) at risk are weighted by either fixed or time-varying inverse-sampling-
weights (ISW) to account for subcohort sampling.
Later, methods that seek to utilize some of the phase 1 covariate information were pro-
posed. Borgan et al. [2000] considered a stratified sampling by a phase 1 variable which
is a correlate of exposure, to incorporate statum-specific ISW in the estimating equation.
Stratum-specific ISW can be calculated using empirical sampling fraction within each stra-
tum. They proposed three different estimating equations by considering different types of
weights. Simulation studies suggested that the stratified estimator II with time-varying
ISW, referred to as BII estimator from herein, is the most efficient among the existing esti-
mators. Kulich and Lin [2004] established asymptotic theory for the BII type of estimators.
In addition they proposed a new class of weighted estimators with general time-varying
ISW; doubly weighted (DW) estimator and combined doubly weighted (CDW) estimator.
The methods involve a modeling step for prediction of the values of each partially missing
phase 2 variables, and is likely of greatest use when there are only 1 or 2 such variables.
The authors suggest to use CDW estimator in practice as DW estimator is efficient only if
a model to predict the phase 2 variables given all the phase 1 variables is correct. Briefly,
the CDW estimator can be calculated through five steps:
1. Stratify by a correlate (referred to as surrogate in Kulich and Lin [2004], which is
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a part of phase 1 variable) of a phase 2 variable. Stratification can be done using
non-surrogate phase 1 variables as well, however, the stratification must incorporate
a surrogate.
2. Develop models using subcohort controls data for prediction of the phase 2 variables
and obtain estimated values of the missing phase 2 variables.
3. Evaluate time-varying ISW for all subjects.
4. Obtain BII estimator and estimate several covariance functions evaluated at the value
of BII estimator to obtain a weight matrix which will affect on efficiency of CDW
estimator.
5. Iteratively solve a proposed estimating equation with plugging-in BII estimator as an
initial value. The proposed estimating equation involves the weight matrix mentioned
above.
Numerical studies indicated that the CDW estimator is more efficient than other existing
estimators such as Chen and Lo [1999], Borgan et al. [2000], and Chen et al. [2001]. The
efficiency gain for the phase 2 covariates depends on the ability of the first-phase data to
predict the true values of the partially missing variables. Later, Breslow et al. [2009a] and
Breslow et al. [2009b] considered adjustment of ISW by calibration or estimation which
making use of phase 1 covariate information. Calibration method adjusts ISW to be as
close as possible to the sampling weights subject to a constraint that the cohort total of
V equals to its weighted sum among sampled subjects. Estimation methods uses ISW as
inverse of inclusion probabilities estimated from a logistic regression model that predicts
which cohort subjects are sampled at phase 2. Simulation study and real data analysis
reported by Breslow et al. [2009b] showed that such adjustment on ISW can dramatically
improve precision of estimation for baseline covariates effects (i.e., a part of phase 1 variables
that are known for all) on an outcome. They also showed that the methods can improve
precision of estimation for phase 2 covariates effects when there exists a strong surrogate
for the partially missing covariates.
While Barlow [1994] and Barlow et al. [1999] considered only time-varying ISW to
improve efficiency, the rest of methods seek to make better use of information that are
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available from all subjects by stratification using phase 1 variables that are correlated with
the phase 2 variables. However, aforementioned methods showed efficiency improvement
for either baseline or phase 2 hazard ratio estimation. Under a biomedical observational
study in the presence of confounding, we are in slightly different situation that we have
primary exposure (typically, treatment) which is available from all subjects but missing
confounders information at phase 2. Primary interest lies on evaluating effect of time-
varying treatment on a predefined outcome while marginal effect of phase 2 variables on the
outcome is less important. Rather, the phase 2 variable information is used to account for
confounding. Therefore, some of the methods described above may not be applicable (or
useful) to improve efficiency of hazard ratio estimation of treatment in MSCM case-cohort
analysis.
In this paper we describe how the aforementioned methods that are developed in the
standard associational context can be extended to the causal setting, and discuss why some
of the methods cannot be readily applicable to the causal setting. In addition, we propose
a new method to improve efficiency in the MSCM case-cohort analysis, which incorporates
use of all subject in the full cohort. The rest of this paper is organized as follows: In §4.2,
we describe general methods to obtain consistent and asymptotically normally distributed
MSCM estimators under both the full and the case-cohort settings [Lee et al., 2013]. In
§4.3, we demonstrate how the general methods can be combined with some of the discussed
methods in this section, and why some of the discussed methods cannot be applicable to
the causal setting. A new method to improve efficiency is discussed. In §4.4, we report the
results of our simulation studies, and illustrate the proposed methods with an example. We
finalize this paper with discussion in §4.5.
4.2 General Methods for MSCM Case-Cohort Estimators
We assume a study comprised of n different individuals indexed by i, which aims to
evaluate the effect of treatment on a time to event outcome. Capital letters will represent
random variable and lower letters will represent values of variables or constants. Subject
index i may be suppressed when there is no ambiguity. Let T be a failure time, C be a
censoring time, and ∆ = I(T ≤ C). Define observed time X = min(T,C), counting process
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N(t) = I(X ≤ t,∆ = 1), and at risk process Y (t) = I(X ≥ t). A subject whose failure time is
observed (i.e., ∆i = 1 andXi = Ti) is referred to as a case, and a censored subject (i.e., ∆i = 0
and Xi = Ci) is referred to as a control. Let A(⋅) be a p-vector of treatment process, let L(⋅)
be a p-vector of covariate process, and let V be baseline covariates which may be a part of
L(0). Consider a study conducted from time 0 to time 1 where measurements are collected at
c different times. Assume L(t) is temporally prior to A(t), i.e., decision of treatment is made
after obtaining covariate information at time t ∈ [0,1]. We use overbar notation to represent
history up to and including time t; A(t) = {A(u) ∶ 0 ≤ u ≤ t}, L(t) = {L(u) ∶ 0 ≤ u ≤ t}, etc.
Let a denote each possible static treatment plan, i.e., a = {a(t) ∶ 0 ≤ t ≤ 1}. Define Ta to be
a subject’s potential failure time had the subject been treated according to the plan a, and
C(⋅) to be a censoring process so that Ci(t) is a censoring indicator, i.e., Ci(t) = 0 means
that subject i is alive at time t and Ci(t) = 1 means that subject i is not alive at time t.
Suppose that C(t) is conditionally independent of T
a,C(1)=0 given A(t−) and L(t−). Under
the usual causal assumptions such that causal consistency, conditional exchangeability, and
positivity, we can obtain the causal effect of a function of treatment using MSCMs, which
are given by
λTa(t) = λ0(t) exp{β′0f(a(t))}
where λTa(t) is the hazard of failure at time t if all individuals in the population had
followed treatment plan a through time t, λ0(t) is an unspecified baseline hazard function
corresponding to the hazard if all individuals had been untreated through time t, f(a(t))
is a user-specified function of treatment history up to time t, and β0 is an unknown relative
risk parameter vector. For notational convenience, consider the following MSCMs,
λTa(t) = λ0(t)r{β′0a(t)}, (4.1)
i.e., let us focus on the causal effect of current treatment a(t), using notation r{⋅} instead of
exp{⋅}. In the presence of confounding, we consider weight process W (⋅) the form of which
at time t is given by
W T (t) =∏
k≤t
pr[A(k)∣A(k−)]
pr[A(k)∣A(k−),L(k)] .
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Under the assumptions of conditional exchangeability and positivity, W can consistently
be estimated at any time t ∈ [0,1]. In the presence of censoring, we can further account
for the bias due to censoring via weighting a subject alive and uncensored at time t using
estimates of W T (t) ×WC(t), where
W T (t) =∏
k≤t
pr[A(k)∣A(k−),C(k−) = 0]
pr[A(k)∣A(k−),L(k),C(k−) = 0], and
WC(t) =∏
k≤t
pr[C(k) = 0∣C(k−) = 0,A(k−)]
pr[C(k) = 0∣C(k−) = 0,A(k−),L(k)] .
From now on, consider the following weight process
W (t) =W T (t) ×WC(t), (4.2)
which is referred to as inverse-probability-weights (IPWs). By further assuming the posi-
tivity on censoring, (4.2), can consistently be estimated.
With full data, β0 in (4.1) would be estimated by solving the following weighted esti-
mating equation:
UF (β) =
n
∑
i=1
∫
1
0
Wi(t)[Ai(t) −EW(1)(t, β)]dNi(t) = 0, (4.3)
which is the weighted partial likelihood score function, where for j = 0,1,2, and k = 1,2,
EW(1)(t, β) = S
(1)
W(1)
(t, β)/S(0)
W(1)
(t, β),
S
(j)
W(k)
(β, t) = n−1
n
∑
l=1
Wl(t)kYl(t)r(j){β′Al(t)},
r(j){β′Al(t)} = Al(t)⊗jr{β′0Al(t)},
and c⊗j are defined by c⊗0 = 1, c⊗1 = c, c⊗2 = cc′ for a p × 1 vector c.
Consider a set of individuals C˜ of size n˜ that is randomly selected without replacement
from the full cohort of size n(≥ n˜), i.e., C˜ is a subcohort. With the case-cohort data, we
can consistently estimate β0 in (4.1) by solving either of the following weighted estimating
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equations:
U˜(β) =
n
∑
i=1
∫
1
0
Wi(t)[Ai(t) − E˜W(1)(t, β)]dNi(t) = 0, (4.4)
U∗(β) =
n
∑
i=1
∫
1
0
Wi(t)[Ai(t) −E∗W(1)(t, β)]dNi(t) = 0 (4.5)
where for j = 0,1,2, and k = 1,2,
E˜W(1)(t, β) = S˜
(1)
W(1)
(t, β)/S˜(0)W(1)(t, β),
E∗W(1)(t, β) = S
∗(1)
W(1)
(t, β)/S∗(0)W(1)(t, β)
S˜
(j)
W(k)
(β, t) = n˜−1∑
l∈C˜
Wl(t)kYl(t)r(j){β′Al(t)},
S
∗(j)
W(k)
(β, t) = n˜−1 ∑
l∈C˜∪{i}
Wl(t)kYl(t)r(j){β′Al(t)}.
Asymptotic theories of the full and the case-cohort MSCM estimators obtained by solving
(4.3) - (4.5) have been established by Lee et al. [2013]. As Lee et al. [2013] have shown
that (4.4) and (4.5) are asymptotically equivalent, we mainly focus on adjusting (4.4) to
improve efficiency. Similar arguments can be made based on (4.5).
Cole et al. [2012] used (4.5) to obtain MSCM parameter estimator in simulation studies
and real data analysis. Both simulation and real data analysis results demonstrated that
the case-cohort MSCM parameter estimator is less efficient than the full cohort MSCM
parameter estimator. This is inevitable because we only makes use of partial data due to
phase 2 variables in the case-cohort analysis. In the next section, we describe how existing
methods can be extended to the MSCM case-cohort analysis and why application of some
of the methods would be limited in the causal setting. Then we propose a new method to
improve efficiency in the MSCM case-cohort analysis.
4.3 Improving Efficiency of the Estimation
Let ξ be a binary random variable that indicates the selection of a subject into the
subcohort, and α be the selection probability, i.e., pr(ξ = 1) = α, where α > 0. α is a known
probability as α = n˜/n, however, we can estimate sampling probability at each failure time
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using observed data. For example, we can use αˆ(t) = ∑n˜i=1 Yi(t)/∑ni=1 Yi(t), i.e., number of
subcohort members who are at risk at time t divided by number of full cohort members
who are at risk at time t.
4.3.1 Time-Varying Inverse Sampling Weights
Following Barlow [1994], Barlow et al. [1999], and Borgan et al. [2000], we may improve
efficiency of the MSCM hazard ratio estimation in the case-cohort analysis by solving the
following doubly-weighted estimating equation:
U˜B(β) =
n
∑
i=1
∫
1
0
̺i(t)Wi(t)[Ai(t) − E˜BW(1)(t, β)]dNi(t) = 0, (4.6)
where
̺i(t) =∆i + (1 −∆i)ξi/αˆ(t), (4.7)
E˜BW(1)(t, β) = S˜
(1)
BW(1)
(t, β)/S˜(0)
BW(1)
(t, β),
S˜
(j)
BW(k)
(β, t) = n˜−1∑
l∈C˜
̺l(t)Wl(t)kYl(t)r(j){β′Al(t)}.
(4.7) assigns weight of 1 if subject i is being a case at time t, and assigns weight of αˆ(t)−1
if subject i remains a subcohort control at time t. Consider new IPWs incorporating ̺i(t),
W
†
i (t) = ̺i(t) ×Wi(t),
then (4.6) becomes (4.4) where W †i (t) substitutes for Wi(t). Therefore, we can use the
variance estimator proposed by Lee et al. [2013] or the robust variance estimator by Lin
and Ying [1993] as both of them are shown to perform well in Lee et al. [2013]. When
subcohort size is small, the variance estimator proposed by Lee et al. [2013] is preferable.
Efficiency gain comes from using an estimated sampling probability αˆ rather than using
the known true sampling probability α at a given time [Robins, Rotnitzky and Zhao, 1994].
However, in MSCM analysis, variability coming from adding ̺ to IPWs may attenuate the
efficiency gain due to increase of bias. Simulation results reported by Barlow et al. [1999]
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also indicated that the unweighted analysis using Prentice-type [Prentice, 1986a] likelihood
(which corresponds to (4.5) in causal context) may be preferable due to increase of bias. Our
small simulation study result in §4.4 implies that variability coming from adding another
inverse probability may attenuate efficiency.
Most literature regarding efficiency improvement in the standard case-cohort analysis
seek to make use of various types of ISWs. As described in §4.1, methods proposed by
Borgan et al. [2000]; Kulich and Lin [2004]; Breslow et al. [2009a,b] all make use of time-
varying ISWs as means of improving efficiency. Therefore, application of these method may
not useful to improve efficiency in MSCM case-cohort analysis, especially in the presence
of informative censoring (that IPW involves IPCW as well as IPTW). However, it will be
an interesting project to compare efficiencies of different MSCM case-cohort parameters
obtained based on these methods.
As previously developed methods to improve efficiency in the standard case-cohort anal-
ysis may not be advantageous in the causal setting, we propose a new method that can
improve efficiency in MSCM case-cohort analysis.
4.3.2 Imputation Method
We propose to adopt the multiple imputation (MI) method to improve efficiency in
MSCM case-cohort analysis. One strategy to handling missing data is substituting missing
values using simple imputation and treat imputed values as if they are observed. However,
single imputation does not account for the uncertainty about the predictions of missing
values and estimated variances of the parameter estimates are known to be biased toward
zero. MI replaces each missing value using a set of plausible values reflecting uncertainty of
the imputation model which leads to a valid statistical inference. MI has been recognized
as a practical and flexible method for handling missing data as it becomes widely available
in most statistical packages such as R, SAS, and STATA.
Case-cohort studies can be viewed as a special type of incomplete data, where phase 2
covariates are missing at random (MAR). Therefore, we restrict our interest in imputation
of missing phase 2 covariates, and do not consider missing treatment/outcome. Briefly
speaking, MAR assumes that probability of missingness depends only on observed data
(and is independent of unobserved part of data). This is true for the case-cohort design,
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as phase 2 covariates are missing by (i) failure status which is the observed variable, and
by (ii) subcohort inclusion/exclusion status which is determined by a random mechanism.
In this section we describe MI with MSCM case-cohort studies and present corresponding
maximum likelihood estimator. We also present asymptotic theory of MI estimator based
on two papers, by Wang and Robins [1998] and Robins and Wang [2000]. Chapter 14 of
Tsiatis [2006] is an excellent reference to study large sample theories for MI estimators in
both frequentist and Bayesian perspectives. In what follows, we consider a Bayesian type
estimator, which was referred to as Type A or proper imputation estimator in Wang and
Robins [1998] and Tsiatis [2006].
Notation First, note that A and observed time X are available in practice. Therefore,
we assume that L represents the phase 2 variables and that only L is missing (for non-
subcohort controls) in case-cohort data. Note that L is required to calculate (4.2), but not
to obtain estimator of β0 in (4.1). Let the full cohort data be denoted by Z = {Z1, ..,Zn}
where Zi is assumed iid with density fZ(z, β). Here we slightly abuse notation and Zi can
be written as Zi(1) to be consistent with the previous notation discussed in § 4.2. Let
Ri = 1 if Li(1) is observed and Ri = 0 otherwise, i.e., R denote the indicator of a complete
data (i.e., case-cohort sample inclusion indicator) which is time-invariant. Therefore, the
observed data at the end of study period t = 1 (i.e., case-cohort data) can be expressed as
{Ri,Zi; i = 1, ...n}. More generally, the observed data can be written as
{Ri,GRi(Zi)}, i = 1, ..., n.
where GR is a known function associated with the data coarsening variable R. Hereafter, we
slightly change notation UF (β) given in (4.3), which denote the full cohort score function,
to UF (z, β). We use UF (z, β) notation for imputed full cohort score function as well. In
similar fashion, let U{Ri,GRi(Zi), β} be the observed case-cohort score function, i.e., we
use notation U{Ri,GRi(Zi), β} rather than U˜(β) or U∗(β) in (4.4) or (4.5).
Assumptions We assume that time-varying confounders are continuous. There may be a
case that one of time-varying confounders is binary or categorical. In that case, we assume
that there exists continuous variable that can be mapped to the binary/categorical variable.
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We assume that a (continuous) time-varying confounder is a repeated measurement. In
particular, with a study of τ visits we assume that
Li = (Li(1), ...,Li(τ)) ∼ N(Diψ,Σi) (4.8)
where Di is the design matrix for an individual i based on all available information such
as baseline covariates, treatment history, event/censoring time, with time information for
a fitted repeated measures model. ψ is the regression coefficients and Σi is the covariance
matrix for Li which includes variance-covariance parameters for the model.
MI estimator Assuming a time-varying confounder is a repeated measurement, imple-
mentation of Bayesian MI to a (longitudinal) observational case-cohort study as follows:
We randomly sample each missing value m times from the conditional distribution
fZ ∣Ri,GRi
{z∣Ri,GRi , ψ(j)} (4.9)
where ψ(j) itself is sampled from some distribution, say f{ψ∣Ri,GRi}. Therefore, we first
draw ψ(j) from f{ψ∣Ri,GRi} in the j-th imputation and then draw missing Zi from the
posterior distribution (4.9) evaluated at ψ(j). Simulation of (4.9) is easy if missing pattern
is monotone, i.e., missing Lj for individual i implies that all subsequent variables Lk, k ≥ j
are missing for that individual. In such setting imputation strategy could be flexible and one
can implement regression, propensity [Rubin, 1987], or predictive mean matching [Heitjan
and Little, 1991; Schenker and Taylor, 1996]. Monotone missing assumption is satisfied if
no case-cohort subjects miss any study visits (i.e., there is no missing for the case-cohort
subjects). This could be true if a study has small number of study visits. In our simulation
study, we assume that a time-varying confounder is measured at two consecutive time points
(or three time points if baseline is considered). We consider missing phase 2 variables for
non-subcohort controls only, and therefore we could assume monotone missing pattern (e.g.,
if Li(1) is missing then Li(2) should be missing). If missing pattern is not monotone, the
posterior distribution can be simulated using Markov chain Monte Carlo (MCMC) algorithm
[Schafer, 1997]. In MACS and WHIS studies, case-cohort subjects missed some of semi-
annual visits due to the long term follow-up periods. Therefore, we implement MCMC to
simulate posterior distribution. All methods and algorithms are implemented in proc mi
procedure in SAS version 9.3.
Let Zij be covariate information of i-th individual in the j-th imputed full data where
j = 1, ...,m, i.e., Zij = Zi if Ri = 1 and Zij is a sampled value from posterior distribution
of the missing data if Ri = 0. Let βˆj be the solution to the j-th imputed full data score
equation:
n
∑
i=1
UF{Zij(ψ(j)), βˆj} = 0. (4.10)
Then the MI estimator based on m imputed data sets is defined by
βˆm =m
−1
m
∑
j=1
βˆj (4.11)
and corresponding variance estimator of βˆm proposed by Rubin [1987] is given by
Tm = V¯m + {1 +m−1}Bm, (4.12)
where V¯m = m
−1∑mj=1 Vj, Vj represents standard error associated with βˆj , and Bm = (m −
1)−1∑mj=1(βˆj − βˆm)2 with j = 1, ...,m being the imputation index. The term {1 +m−1}Bm
is associated with between-imputation variance reflecting uncertainty due to sampling vari-
ability. MI procedure based on score equation (4.10) is referred to as proper impuation
by Rubin [1987]. SAS proc mianalyze provides MI estimator (4.11) and corresponding
variance estimate (4.12).
Asymptotic Distribution of MI estimator Under the assumptions of i) proper imputa-
tion, ii) correct model specification for both imputation/analysis models, and iii) with large
samples (i.e., when n goes to infinity), Rubin [1987] (p.86) showed asymptotic distribution
of MI estimator and corresponding variance estimator in Bayesian context; i.e., he showed
asymptotic posterior distribution of βˆ∞ − β0 given observed data follows mean zero normal
distribution, where βˆ∞ = limm→∞ βˆm. In this paper, we present large sample frequentist
property of the Bayesian MI estimator. Results presented in this paragraph are mainly
taken from Chapter 14 of Tsiatis [2006].
73
Under the same assumption as in Rubin [1987], (4.11) is consistent and asymptotically
normally distributed estimator of β0 in the sense that
n1/2(βˆm − β0)→d N(0,Tm),
where Tm is composed of information matrices evaluated at β0. In particular,
Tm =IF (β0)−1 + (m + 1
m
)IF (β0)−1{IF (β0) − I(β0)}IF (β0)−1 (4.13)
+(m + 1
m
)IF (β0)−1{IF (β0) − I(β0)}var[q{Ri,GRi(Zi)}]{IF (β0) − I(β0)}IF (β0)−1.
where I(β) = −E[∂U{Ri,GRi(Zi), β}/∂β′]β=β0 and IF (β) = −E[∂UF (z, β)/∂β′]β=β0 which
denote information matrices based on the observed and the (imputed) full data, respectively,
and q{Ri,GRi(Zi)} is the influence function of initial estimator of β0 (Tsiatis [2006], p.369).
Rubin’s MI variance estimator (4.12) converges in expectation to Tm when n goes to
infinity. In addition, when m goes to infinity, (4.12) is a consistent and asymptotically
unbiased estimator of limm→∞ Tm (Tsiatis [2006], p.370-371).
Caution When we refer asymptotic properties (i.e., asymptotic bias, consistency, etc) from
herein, we assume that n goes to infinity but m can be finite unless otherwise stated.
Rubin’s variance estimator is asymptotically unbiased (i.e., converge in expectation to
its asymptotic variance) when MI is done using Bayesian approach. It is important to
distinguish this approach with frequentist approach of MI. Frequentist approach fixes ψ(j)
in (4.10) at maximum likelihood estimator of ψ, say ψˆ, and sample at random from the
conditional distribution fZ ∣Ri,GRi
{z∣Ri,GRi , ψˆ} to obtain random quantities Zij , j = 1, ...,m.
This approach was referred to as improper imputation by Rubin. Bayesian MI introduces
additional variability coming from sampling ψ(j) from its posterior distribution at each
imputation and is less efficient than frequentist MI approach. Therefore, Rubin’s variance
estimator will be biased when missing data is filled by improper imputation. Wang and
Robins [1998] and Robins and Wang [2000] showed asymptotic distribution theories of im-
proper imputation estimators and described estimation of asymptotic variance. Although
frequentist MI is more efficient approach with finite m, no statistical packages or built-in
procedures are available to obtain variance estimator of the MI estimator. In addition,
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application of Wang and Robins [1998] or Robins and Wang [2000] on longitudinal study
data requires calculation of score function with respect to the variance-covariance param-
eters associated with repeated measurements to evaluate influence function. This involves
highly complex analytic form when repeated measurement is considered. As difference be-
tween frequentist and Bayesian asymptotic variance disappears as m goes to infinity we
recommend implementing Bayesian MI approach with as big m as software and computing
time allows. Chapter 14 (p.366- 369) of Tsiatis [2006] is a great reference to see asymptotic
property of Rubin’s variance estimator (4.12) and to see it compared to that of frequentist
MI estimator.
Rubin [1987] stated that it is important to include all variables that are likely to be used
in final analysis model (which is in this case, MSCM); leaving out some variables that are
believed to be weak predictors implies that (we are certain that) those variables have no
relation with the missing data. In MSCM MI analysis, we know that variables associated
with time-to-event outcome (such as baseline covariates, treatment status, and confounders
themselves) induce the missing data. Therefore, we include all available information that are
used to model to calculate IPW and used in MSCM when imputation model is considered.
As MI requires a correct imputation model specification Rubin [1987], sensitivity analysis
for different model specifications or different imputation methods might be of interest to
check the model assumption. Regression and MCMC methods discussed above assume
multivariate normality (4.8). However, it is known that inference based on MI can be
robust to departure from the assumption when missing fraction is not large [Schafer, 1997].
Therefore, departure from (4.8) assumption may be ignorable with high subcohort fraction.
4.4 Results
Below, we present simulation study and real data analysis results.
4.4.1 Simulation Studies
First, we show a small simulation study result based on doubly-weighted method using
time-varying ISW, (4.6), in Table 4.1. Performance of the estimator based on (4.6) was
compared to Lee et al. [2013]’s estimator which is based on estimating equation (4.4). As
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W † is still predictable, variance formula proposed in Lee et al. [2013] was employed to
calculate standard error.
To compare performance of doubly-weighted estimator and Lee et al. [2013]’s estimator,
we adopt the same simulation setting as in Cole et al. [2012], except censoring mechanism.
Cole et al. [2012] generated censoring times according to administrative censoring mech-
anism, while we generated censorings from uniform distributions with support chosen to
achieve the desired event rates. For details of the simulation setting, see Cole et al. [2012].
Briefly, we generated potential survival times when never exposed to treatment T∞, when
treated from baseline T0, and when treated from t1, Tt1 , by following Cole et al. [2012], with
baseline hazard being 1 and t1 being 0.1, for cohorts of size n = 1,000. Then we generated
baseline treatment status, say A0, from Bernoulli(1/3). Then two time varying confounders,
say L1 and L2 were generated; L1 was generated from Bernoulli with probability dependent
on A0 and T∞ where marginal probability equals 0.5. A second time-varying confounder
was generated from standard normal distribution dependent on A0 and T∞. Note that, L1
is a binary and L2 is continuous variable respectively. Finally, we generated a time-varying
exposure at time t1 = 0.1, say A3, from Bernoulli with probability dependent on L1 and L2,
where marginal probability equals 0.5, for the two-thirds of subjects who were unexposed
at baseline.
We set event rate to be 20% and randomly sampled 20% of subjects to form a subcohort.
We generated 200 datasets under the null β0 = 0 and the alternative β0 = log(1/2) ≈ −0.693;
β denotes the treatment effect parameter. Table 4.1 shows that the doubly-weighted es-
timating equation worsened the efficiency compared to (4.4). ESEs under the null and
the alternative were bigger than those based on (4.4), and MSEs were bigger as well. As
mentioned in §4.3.1, the simulation result may imply that variability coming from adding
another inverse probability may attenuate efficiency in MSCM case-cohort analysis.
To see performance of the proposed MI estimator (4.11), we considered several different
scenarios by varying subcohort fraction 10, 20, and 30%, and event rates from 10, 15, 20,
and 25%. At each scenario, we generated 1,000 datasets under the null β0 = 0 and the
alternative β0 = log(1/2).
In this simulation we combined simulation settings in Cole et al. [2012] and Moodie et al.
[2008]. Moodie et al. [2008] compared different methods to handle missing exposure data
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Table 4.1: Simulation studies to compare performance of estimators
Null Bias ASE ESE MSE Cover Power
(4.4) -0.029 0.236 0.206 0.056 0.975 0.020
(4.6) -0.032 0.253 0.217 0.065 0.970 0.025
Alternative
(4.4) -0.044 0.236 0.236 0.057 0.955 0.880
(4.6) -0.099 0.250 0.23 0.072 0.940 0.895
Simulation studies to compare performance of estimators based on (4.6) with (4.4) when
event rate and subcohort fraction equaled to 20%. Bias denotes the empirical bias of the
different estimators based on (4.6) and (4.4). ASE denotes average of estimated standard
errors. ESE denotes the empirical standard errors (i.e., average standard error of the
estimators). MSE denotes the mean squared error calculated by {Bias2 +ASE2}. Cover
denotes the empirical coverage of 95% Wald-type confidence intervals using Lee et al.
[2013]’s variance estimator. Size/power denotes the proportion of simulated data sets
where the hypothesis β0 = 0 was rejected.
in marginal structural models, which is different missing data type than what we consider
in this article. Potential survival times T∞, T0, and Tt1 were generated as described above
with baseline hazard set to be 1 and t1 set to be 0.1, for cohorts of size n = 1,000. Then we
generated time-varying confounders and time-varying treatment by mimicking Cole et al.
[2012] and Moodie et al. [2008]. A baseline covariate, say L0, was drawn from Normal(3,
1) and a first time-varying confounder L1 was drawn from Normal(10, 1). Then treatment
status at time 0 (A0) was generated from Bernoulli with probability dependent on L1 where
marginal probability equals 1/3. A second time-varying confounder L2 was drawn from
Normal(L1 + β0A0, 1). Treatment status at time 1 (A1) was generated from Bernoulli with
probability dependent on L2 and A0, where marginal probability equals 0.5, for the two-
thirds of subjects who were unexposed at baseline. Censoring times were from uniform
distributions. For more details about the simulation setting, see Cole et al. [2012] and
Moodie et al. [2008].
We assumed that A0 and A1 were available from all subjects in the study. To impute
missing phase 2 covariates L1 and L2 for non-subcohort controls, we used all available in-
formation L0,A0,A1, and observed time X from subcohort controls. We choose small m
(m = 5) because we considered 15 different scenarios which required us extensive computa-
tion time. However in the real data analysis, we considered number of imputation m = 100.
All MI analyses were done using proc mi and mianalyze procedures in SAS 9.3.
Table 4.2 - 4.4 show simulation results when subcohort sampling rates range from 10 to
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30%. Numerical studies indicate that the proposed method can improve efficiency compared
to Cole et al. [2012]. Empirical standard errors obtained by MI analysis are smaller than
those of the case-cohort analysis and are close to those of the full cohort analysis in all
scenarios. Bias based on MI are sometimes bigger than the case-cohort analysis, especially
when event rate is relatively high (e.g., see bias when subcohort fraction is 10 or 20%
and event rate 25%). Nonetheless, MSE values indicate that increase of bias are offset
by efficiency gain. All three analysis methods exhibit correct coverage and power in all
settings. Due to the efficiency gain, MI analysis is more powerful than the case-cohort and
is as powerful as the full analysis.
4.4.2 Real Data Analysis
Study Cohort
We applied the proposed imputation method to a (combined) dataset comprised of
HIV positive patient collected from the Multicenter AIDS Cohort Study (MACS) and the
Women’s Interagency HIV study(WIHS). The full cohort data analysis is consistent with
that of Cole et al. [2012]. Readers who are interested in detailed information about study
cohort is referred to Cole et al. [2012]. Briefly, participants in both studies were followed-up
approximately every 6 months. While average years of follow-up was approximately 8 years,
maximum years of follow-up was 12 years and thus maximum number of visits was 24. At
each semiannual study visit, participants went through a physical examination, provided a
blood sample, and completed a questionnaire about use of antiretroviral therapy, etc.
In the real data analysis, we aimed to estimate the effect of highly active antiretroviral
therapy (HAART) initiation with acquired immunodeficiency syndrome (AIDS) incidence
or death while adjusting for (confounding) effects of CD4 counts and HIV-1 RNA viral
loads. To this end, we constructed a full cohort from the MACS and WIHS data which
includes 950 HIV-1-seropositive men and women who were alive and not using antiretroviral
therapies in April 1995 (because the first highly active regimen was approved on December
6, 1995). There were 211 incident AIDS or death (henceforth cases, 22%) in the full cohort.
We selected a 20% random sample without replacement from the full cohort size of 950 using
the same seed number as in Cole et al. [2012]. Among the 190 subcohort subjects, there
were 47 cases (25%). The case-cohort consisted of 354 subjects, defined by 190 subcohort
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Table 4.2: Simulation studies to compare performance of estimators when α = .1
Null Subcohort Event Bias ASE ESE MSE Cover Size/
fraction (%) rate (%) Bias Power
Full 10 10 -0.004 0.212 0.218 0.045 0.949 0.051
Imputation -0.003 0.213 0.219 0.045 0.952 0.058
Case-Cohort -0.021 0.291 0.294 0.085 0.948 0.052
15 -0.002 0.170 0.173 0.029 0.945 0.055
-0.001 0.172 0.173 0.030 0.947 0.053
-0.011 0.257 0.254 0.066 0.954 0.046
20 -0.002 0.146 0.146 0.021 0.956 0.044
0.000 0.148 0.146 0.022 0.957 0.043
-0.006 0.242 0.239 0.059 0.952 0.048
25 -0.002 0.130 0.129 0.017 0.961 0.039
0.001 0.133 0.129 0.018 0.963 0.037
-0.003 0.235 0.235 0.055 0.948 0.052
Alternative
Full 10 10 -0.020 0.239 0.249 0.058 0.954 0.873
Imputation -0.019 0.240 0.250 0.058 0.952 0.868
Case-Cohort -0.024 0.307 0.319 0.095 0.946 0.640
15 -0.017 0.185 0.189 0.035 0.945 0.977
-0.014 0.188 0.190 0.035 0.952 0.971
-0.013 0.266 0.269 0.071 0.953 0.749
20 -0.014 0.156 0.159 0.024 0.948 0.993
-0.010 0.159 0.160 0.025 0.952 0.991
-0.006 0.249 0.250 0.062 0.959 0.799
25 -0.013 0.137 0.140 0.019 0.949 0.999
-0.010 0.140 0.140 0.020 0.951 0.997
-0.004 0.241 0.240 0.058 0.950 0.819
Simulation studies to compare performance of estimators based on full cohort score
equation (4.3), multiple imputation, and case-cohort score equation (4.5) when subcohort
fraction equals 10%. Bias denotes the empirical bias of the different estimators of β0. ASE
denotes average estimated standard error. ESE denotes the empirical standard errors,
which is defined by standard deviations of 1,000 log hazard ratio estimates. MSE denotes
the mean squared error calculated by {Bias2 +ESE2}. Cover denotes the empirical
coverage of 95% Wald-type confidence intervals using the robust variance estimator.
Size/power denotes the proportion of simulated data sets where the hypothesis β0 = 0 was
rejected.
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Table 4.3: Simulation studies to compare performance of estimators when α = .2
Null Subcohort Event rate Bias ASE ESE MSE Cover Power
Full 20 10 -0.011 0.207 0.217 0.043 0.954 0.046
Imputation -0.010 0.207 0.217 0.043 0.952 0.048
Case-Cohort -0.020 0.246 0.269 0.061 0.916 0.084
15 -0.013 0.171 0.174 0.029 0.948 0.052
-0.012 0.171 0.174 0.029 0.948 0.052
-0.020 0.214 0.224 0.046 0.928 0.072
20 -0.012 0.146 0.142 0.021 0.960 0.040
-0.011 0.147 0.142 0.022 0.958 0.042
-0.008 0.195 0.193 0.038 0.956 0.044
25 -0.010 0.130 0.127 0.017 0.964 0.036
-0.009 0.131 0.127 0.017 0.966 0.034
-0.015 0.185 0.188 0.034 0.942 0.058
Alternative
Full 20 10 -0.006 0.230 0.232 0.053 0.946 0.886
Imputation -0.006 0.231 0.232 0.053 0.948 0.878
Case-Cohort -0.013 0.264 0.249 0.070 0.964 0.806
15 -0.002 0.185 0.190 0.034 0.946 0.974
-0.001 0.186 0.190 0.034 0.944 0.972
-0.005 0.225 0.215 0.050 0.960 0.904
20 0.012 0.155 0.156 0.024 0.946 0.988
0.013 0.156 0.156 0.025 0.948 0.988
0.011 0.202 0.194 0.041 0.966 0.944
25 0.008 0.136 0.143 0.019 0.946 1
0.010 0.137 0.143 0.019 0.950 1
0.009 0.190 0.187 0.036 0.954 0.962
Simulation studies to compare performance of estimators based on full cohort score
equation (4.3), multiple imputation, and case-cohort score equation (4.5) when subcohort
fraction equals 20%.
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Table 4.4: Simulation studies to compare performance of estimators when α = .3
Null Subcohort Event rate Bias ASE ESE MSE Cover Power
Full 30 10 -0.004 0.212 0.218 0.045 0.949 0.051
Imputation -0.004 0.212 0.219 0.045 0.948 0.052
Case-Cohort -0.005 0.235 0.243 0.055 0.947 0.053
15 -0.002 0.170 0.173 0.029 0.945 0.055
-0.002 0.171 0.173 0.029 0.946 0.054
-0.002 0.197 0.197 0.039 0.942 0.058
20 -0.002 0.146 0.146 0.021 0.956 0.044
-0.001 0.146 0.146 0.021 0.958 0.042
0.000 0.176 0.175 0.031 0.958 0.042
25 -0.002 0.130 0.129 0.017 0.961 0.039
-0.001 0.130 0.129 0.017 0.963 0.037
0.001 0.164 0.161 0.027 0.965 0.035
Alternative
Full 30 10 -0.020 0.239 0.249 0.058 0.954 0.873
Imputation -0.020 0.239 0.249 0.058 0.956 0.873
Case-Cohort -0.024 0.259 0.270 0.067 0.945 0.810
15 -0.017 0.185 0.189 0.035 0.945 0.977
-0.017 0.186 0.189 0.035 0.949 0.977
-0.017 0.209 0.214 0.549 0.948 0.928
20 -0.014 0.156 0.159 0.024 0.948 0.993
-0.013 0.156 0.159 0.025 0.951 0.993
-0.014 0.185 0.189 0.034 0.949 0.968
25 -0.013 0.137 0.140 0.019 0.949 0.999
-0.012 0.137 0.140 0.019 0.951 0.999
-0.013 0.170 0.172 0.029 0.951 0.985
Simulation studies to compare performance of estimators based on full cohort score
equation (4.3), multiple imputation, and case-cohort score equation (4.5) when subcohort
fraction equals 30%.
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subjects plus the 164 cases that were not selected in the subcohort. The outcome of interest
was time to AIDS or death from any cause and the time-varying confounders were CD4
counts and HIV-1 RNA viral loads. Full cohort data included 9,172 person-visit records
in total and case-cohort collected about 32% of the full cohort data (2,911 person-visit
records), which lead to impute about 68% (6,261) of missing CD4 and viral load records
along the course of study.
In the MI analysis, missing CD4 and viral load information for non-subcohort controls
was imputed 100 times using proc mi procedure in SAS 9.3. As in simulation studies, we
only used subcohort controls to build the posterior predictive distribution of missing data.
We assumed that baseline CD4 or viral load information was available from all subjects, and
used all available information such as treatment history (ever exposed to ART (yes/no)),
gender, race, age (at study entry), and CD4 and viral load at baseline in MI analysis. Results
based on m = 100 imputation results were summarized by proc mianalyze procedure in
SAS 9.3, which makes use of Rubin’s variance formula (4.12).
As a sensitivity analysis, we randomly selected subcohort 100 times by varying seed
number from 1 to 100 using SAS 9.3. In this analysis, we aimed to account for sampling
variability of subcohort in addition to checking against the robustness of the MI and the
case-cohort analyses.
Results
Full cohort subjects characteristic is the same as in Cole et al. [2012] as we used the
same dataset. The dataset consists of 61% women, 59% African American. The mean age
of the full cohort participants at study entry was 39 years with standard deviation (SD)
of 8, a CD4 cell count of 498 cells/mm3 with SD of 279, and a log of HIV-1 RNA level
(henceforth log of viral load) of 4.5 copies/mL with SD of 0.7 for detectable viral load
values; there were 26% of missing in viral load values. The subcohort subjects had similar
baseline characteristics at study entry (Table 4.5).
The full cohort analysis result is consistent with the previously reported result of Cole
et al. [2012]. The inverse probability weighted hazard ratio for incident of AIDS or death
was 0.41, with 95% confidence interval (CI) (0.26, 0.65). Standard error for log hazard
ratio obtained by using the robust standard error was 0.23. In the MI analysis with 100
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Table 4.5: Baseline characteristics of the full and the 50% subcohort subjects
Baseline Characteristic cohort (n=950) Subcohort (n=475)
% Mean (SD) No. % Mean (SD) No.
Mean age (years) 39 (8) 39 (8)
Female sex 61 578 58 111
African-American race 59 560 59 113
Mean CD4 cell 498 (279) 500 (260)
(no. of cells/mm3)
Mean log10viral load 4.5 (0.7) 3.9 (1.1)
(no. of copies/mL)
Baseline characteristics of the full and the 50% subcohort participants at study entry.
Table 4.6: Full cohort, 20% subcohort with MI, and case-cohort MSCM analyses
Analysis Hazard Ratio 95% Confidence Interval (CI) Standard Error (SE)
Full Cohort 0.41 0.26, 0.65 0.23
MI 0.48 0.30, 0.78 0.24
Case-Cohort 0.47 0.26, 0.83 0.29
Full cohort, 20% subcohort with MI, and case-cohort MSCM analyses of the causal effect
of HAART initiation and incident AIDS or death among 950 men and women infected
with HIV type 1 in the MACS and WIHS study, 1996-2007.
imputations, estimated hazard ratio was 0.48 with 95% CI (0.30, 0.78) and standard error
of the log hazard ratio was 0.24; increase of standard error compared to the full cohort
analysis was only 0.01, and width of the CI was slightly wider than that of the full cohort
analysis (0.48 compared to 0.39). Estimated hazard ratio using the case-cohort analysis was
0.47, with standard error of the log hazard ratio 0.29. Compared to the full cohort analysis,
increase in standard error of the case-cohort analysis was 0.07, and width of 95% CI was
0.57, which is about 1.5 times and 1.24 times wider than those of the full cohort and the
MI analyses. As expected, analysis results for the MI MSCM analysis recovered much of
the precision lost in the case-cohort analysis.
Table 4.7 shows sensitivity analysis of MI and the case-cohort analyses results using
100 randomly selected (20%) subcohorts. Reported estimates for case-cohort and for im-
putation analyses are averaged estimates. Considering full cohort result a gold standard,
estimated hazard ratios based on imputation method and case-cohort analyses are slightly
biased. Standard error based on the MI analysis with 100 imputations was about 1.21 times
(0.29/0.24) smaller than that of the case-cohort analysis, yielding 1.27 times narrower 95%
CI. Difference in standard errors of the full cohort and the MI analyses is only 0.1. Results
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Table 4.7: Sensitivity analysis of case-cohort and multiple imputation
Analysis Hazard Ratio 95% Confidence Interval (CI) Standard Error (SE)
Full Cohort 0.41 0.26, 0.65 0.23
MI 0.50 0.32, 0.81 0.24
Case-Cohort 0.50 0.28, 0.90 0.30
Sensitivity analysis of case-cohort and multiple imputation (with 100 imputation) based
on 100 random subcohorts sampled by varying seed number 1 to 100 in SAS. CI denote
95% Wald confidence interval. Standard error for multiple imputation was calculated
based on Rubin’s formula (1987) through MI analyze procedure in SAS.
in Table 4.7 implies that we could recover much of the precision lost from the case-cohort
sampling by implementing the MI method.
4.5 Discussion
The proposed method is valid for a special type of primary exposure such that it can
readily be obtained from existing study data repository. When treatment is the primary
exposure, treatment assignment status or level of the treatment information given to a par-
ticipant can be obtained with relatively less much cost and efforts than expensive covariate
information. However, the proposed method is not suitable for studies in the presence of
missing primary exposure in addition to phase 2 variables. For example, consider a study
that aims to evaluate genetic variant on time to event response. One cannot readily obtain
the genetic information from repository as much cost is required to validate the genetic
information from the blood sample.
The proposed method aims to utilize information on all subjects in the estimating equa-
tion, and therefore it seeks to fill in missing IPWs for non-subcohort controls by imputing
missing phase 2 covariates. Intuitively, this method is valid as the subcohort is selected
at random from the full cohort; the phase 2 variables are missing completely at random.
Therefore, estimated values of partially missing covariates based on the random sample of
the full cohort should not deviate too much from the true values if (1) the sampling was
truly done in random fashion, and (2) imputation model is a correct model when parametric
model is used, or nonparamteric estimation is used. Simulation results indicated that para-
metric methods to estimate missing phase 2 variables can easily fail to improve efficiency
when phase 2 variables are continuous.
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The imputation method differs from the previously developed methods (in the standard
associational context) which seek to utilize information available from the full cohort. In
addition, we seek to make use of all subjects in the estimating estimation to improve effi-
ciency in the case-cohort analysis. We do not require separate surrogate measurements of
phase 2 variables as in Borgan et al. [2000]; Kulich and Lin [2004]; Breslow et al. [2009a,b],
but time-varying confouders themselves can serve as surrogates (e.g., baseline CD4 or viral
load can serve as surrogate of the following CD4 or viral load information).
The proposed estimator would be more efficient than estimators based on (4.4) or (4.5),
because we use all subjects in the estimation step. Further, it could sometimes be more
efficient than the full cohort estimator if imputed values are less variable than the true
values (this is possible in some range of covariates). Nonetheless, bias would become bigger
in such cases so MSE compared to the full cohort analysis would be larger.
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Chapter 5
Summary and Future Research
In summary, we considered estimating the causal hazard ratios of MSCMs via inverse
probability weighting in full cohort and the case-cohort studies. We established asymp-
totic theories for estimators that maximize corresponding WPPLs under certain regularity
conditions, via martingale and counting process formulation. In addition we proposed new
variance estimators which could be more accurate than the robust variance estimators when
sample size is small. Framing the problem using standard counting process and martingale
theory readily enables practical implementation of the methods using existing survival anal-
ysis software. However, implementing MSCM for the case-cohort design was shown to be
not fully efficient. Therefore, we explored an imputation method that could lead to more
efficient inference in the case-cohort MSCM analysis.
As we framed the problem of estimating the causal hazard ratios of MSCMs using
counting processes and martingales, we may consider fitting MSCMs to data from nested
case-control studies or in the presence of competing risks as next projects. Also, researchers
have found that a main challenge of implementing MSMs in practice is difficulty in esti-
mating inverse probability weights [Cole and Herna´n, 2008; Howe et al., 2011; Kang and
Schafer, 2007; Lefebvre, Delaney and Platt, 2008; Mortimer et al., 2005]. It has been shown
that results of using MSMs via inverse-probability-weighting could be highly sensitive to
model misspecification of treatment assignment model, when even number of study visits
is moderate. Therefore, doubly-robust-estimation of the causal hazard ratio of MSCMs in
the presence of case-cohort sampling, or combining covariate balancing propensity score
method proposed by Imai and Ratkovic [2014] in the inverse-probability-weighted estima-
tion of MSCM hazard ratio could be a topic of future work.
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